



المجلس الصحي السعودي
Saudi Health Council

KINGDOM OF SAUDI ARABIA
SAUDI HEALTH COUNCIL
NATIONAL CANCER CENTER
SAUDI CANCER REGISTRY

**CANCER INCIDENCE
REPORT
SAUDI ARABIA**

2020



المجلس الطبي السعودي
Saudi Health Council



KINGDOM OF SAUDI ARABIA
SAUDI HEALTH COUNCIL
NATIONAL CANCER CENTER
SAUDI CANCER REGISTRY



CANCER INCIDENCE
REPORT
SAUDI ARABIA
2020



In the Name of Allah, the Most Gracious, the Most Merciful

The National Cancer Center (NCC) of the Saudi Health Council, presents the annual Cancer Registry report of the year 2020 that outlines the recent achievements of the registry head office, its activities and programs. The Saudi Cancer Registry (SCR) reports support the efforts made in the fight against cancer, and provide those in-charge of cancer healthcare and educational projects with the accurate cancer information that reflect the situational analysis of cancer in Saudi Arabia. This data represents the actual situation of cancer cases in the Kingdom and identifies the most common types based on gender, age, and geographical location.

The reports of the registry allow decision-makers to plan the development of cancer healthcare and health promotion programs to control cancer, aligned with the national strategies and healthcare objectives. Inspired by Vision 2030 to achieve the goals of the ambitious leadership, and the expectations of beneficiaries, healthcare coordination and integration is the prime goal of the Saudi Health Council that strengthen healthcare provision.

In conclusion, the witnessed progress in our beloved country's healthcare sector is a blessing from Allah the Almighty and then, the result of the support of the ambitious leadership of the Custodian of the Two Holy Mosques, and the Royal Highness, the Crown Prince, May Allah protect them, and the close follow-up by his Excellency the Chairman, and the members of the Saudi Health Council. I would like to express my sincere gratitude to my colleagues at the Saudi Health Council, represented by National Cancer Center (NCC), for their diligent work and continuous efforts in preparing this report and achieving the mission and objectives of the Saudi Cancer Registry. I would also like to extend my appreciations to all healthcare staff, organizations, institutions, and charity that involved in healthcare provision and raising awareness to alleviate cancer burden in Saudi Arabia.

Dr. Nahar M. Al-Azemi
Secretary General of the Saudi
Health Council



Praise be to Allah, the Lord of the Worlds, and blessings and peace be upon the noblest of all mankind and upon all his family and companions and those who followed them with goodness until the Day of Judgment.

National Cancer Center (NCC) at the Saudi Health Council plays important roles in collecting, compiling and analyzing data on cancer cases in the Kingdom of Saudi Arabia for the year 2020 and ensuring their validity, with the participation of all government and private health sectors in the Kingdom.

National Cancer Center (NCC) is consistently following up on the Registry's fulfillment of its duties, providing administrative and technical assistance and utilizing the accumulated statistics to establish cancer control and treatment priorities. Moreover, National Cancer Center (NCC) is committed to developing suitable national programs to enhance the levels of healthcare provided to cancer patients.

The Saudi Cancer Registry, which was established in 1412 AH / 1992 AD, was one of the first national registers in the Kingdom, as it was subject to the supervision of the Ministry of Health at King Faisal Specialist Hospital and Research Center, which hosted the Registry until it moved to its new headquarters in the Saudi Health Council in 1435 AH / 2014 AD.

The annual report for this year highlights the impact of the COVID-19 pandemic on the number of registered cancer patients in the Kingdom of Saudi Arabia in 2020. Due to the closure periods, there was a 12% decrease in the number of registered cases compared to 2019, which is consistent with the global trend of a 10% to 20% decrease. It is anticipated that there will be an increase in the number of cases in 2021, which may have resulted in delayed diagnoses during the lockdown periods.

To conclude, I am pleased to thank the technical team responsible for preparing and implementing this report, our National Cancer Center (NCC) colleagues and cancer registrars in all health sectors for their efforts in accomplishing this great work. We extend our gratitude to the members of the Scientific Committee and the reviewers of this report for their dedicated efforts towards the Saudi Cancer Registry, aimed at serving the health sector and benefiting both citizens and residents.

Prof. Mushabbab Ali Al-Asiri
General Director Of The Saudi Arabia National
Cancer Center, Saudi Health Council

PREPARED BY

| Mr. Ahmed Al-Rawaji.

Saudi Cancer Registry Supervisor at The Saudi Arabia Cancer Center, Saudi Health Council.

| Mr. Akram Al-Zamzami

Health Data Analyst and Quality Specialist at The Saudi Arabia Cancer Center, Saudi Health Council.

| Mr. Ahmed Al-nemari

Health Data Analyst and Quality Specialist at The Saudi Arabia Cancer Center, Saudi Health Council.

| Mr. Zeyad Al-Shahrani

Health Data Analyst and Quality Specialist at The Saudi Arabia Cancer center, Saudi Health Council.

| Mr. Saleh Al-Alyani

Health Data Analyst and Quality Specialist at The Saudi Arabia Cancer Center, Saudi Health Council.

REVIEWED BY

| Prof. Mushabbab Ali Al-Asiri

General Director Of The Saudi Arabia National Cancer Center, Saudi Health Council.

| Dr. Ali Al-Zahrani

Principal Clinical Scientist / Senior Consultant, Executive Director, Gulf Center for Cancer Control & Prevention, King Faisal Specialist Hospital & Research Center.

| Mrs. Adhwaa Al-Juhani

General Director Assistant Of The Saudi Arabia National Cancer Center, Saudi Health Council.



INTRODUCTION

This is the twenty-third cancer incidence report published by the Saudi Cancer Registry. Previous publications included the Incidence Reports for the years: 1994-1996, 1997-1998, 1999-2000, and yearly reports until 2020.

This report provides statistics on cancer incidence that can be used for better planning and effective measurement of early detection and management of cancer.

THE STRUCTURE OF THIS REPORT CAN BE OUTLINED AS FOLLOWS:

PART I- MATERIALS AND METHODS.

This part of the report contains information about the background and methods of the Saudi Cancer Registry used in collecting and analyzing the data. We present the basics of coding and classification of tumor topography, morphology, and extent of disease at the time of diagnosis. Also, we describe the software programs we have used to analyze the data.

PART II- OVERVIEW OF CANCER INCIDENCE.

Part II presents the overall cancer incidence in Saudi Arabia diagnosed between 01 January and 31 December 2020. Figures, tables, and line/bar charts are used to present cancer distribution by gender and age groups. Morphology distributions for the most common cancers are also presented in tables.

In addition, incidence tables are used to present the total Number of Cases, Age-Standardized Incidence Rate (ASR), Crude Incidence Rate (CIR), and Cumulative Rates (per 100,000 population) by gender for each primary cancer site. Separate bar charts are used to demonstrate the distribution of the most common cancers by gender in each of the 13 administrative regions of Saudi Arabia.

PART III- CANCER INCIDENCE FOR THE MOST COMMON SITES 2020.

In this part, the incidence of the most common cancers reported among Saudi males and females is outlined. For each cancer site, the total number and proportions of all newly diagnosed cases, the ASR, and the corresponding cancer ranking for each gender are also presented. In addition, ASR for the most common cancers among Saudis is compared with the ASR reported from selected developed and developing countries.

PART IV-CANCER INCIDENCE AMONG NON-SAUDIS.

This part presents numbers of cancer cases among the Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in which a large proportion is aged between 25 and 44, especially among males.

PART V- INCIDENCE TABLES

This part contains the following detailed tables for all newly diagnosed cancer types for the Saudis and the non-Saudis diagnosed in 2020.

- Distribution of cancer cases among Saudis by age group and gender.
- Distribution of cancer cases among non-Saudis by age group and gender.
- Cancer Incidence (per 100,000 population) among Saudis by age group and gender.
- Cancer Incidence (per 100,000 population) among non-Saudis by age group and gender.
- Age-standardized incidence rate and relative frequencies among Saudis by cancer site, gender, and administrative regions

PART VI- ARABIC SUMMARY

It is enclosed an Arabic summary of Cancer Statistics in Saudi Arabia for the Year 2020.

TABLE
OF CONTENTS

TABLE OF CONTENTS

Introduction	04
---------------------------	-----------

PART I

MATERIALS AND METHODS	10
------------------------------------	-----------

Background on Saudi Arabia	11
Saudi Cancer Registry	11
Definitions of Statistical Terms	14

PART II

OVERVIEW OF CANCER INCIDENCE, 2020	16
---	-----------

Cancer Incidence in Saudi Arabia, 2020	17
Cancer Distribution Among Saudi Nationals, 2020	19
Cancer Incidence Among Adults (> 14 Years), 2020	25
Childhood Cancer Reported to Saudi Cancer Registry (≤ 14 Years), 2020	28
Distribution of Cancer Cases in 13 Adminis- trative Regions of Saudi Arabia, 2020	34
International Comparison of Age-Standar- dized Incidence Rates	34

PART III

CANCERS INCIDENCE FOR THE MOST COMMON SITES 2020	36
---	-----------

Cancer Incidence for the Most Common Sites, 2020	37
Female Breast Cancer (C50)	38
Colorectal Cancer (C18-C20)	40
Thyroid Cancer (C73)	42
Leukaemia (C91-C95)	44
Non-Hodgkin's Lymphoma (C82-C85; C96)..	46
Hodgkin's Lymphoma (C81)	48
Corpus Uteri Cancer (C54)	50
Brain,CNS Cancer (C70-C72)	52
Lung Cancer (C33 - C34)	54
Liver Cancer (C22)	55

PART IV

CANCER AMONG NON-SAUDI 2020	60
--	-----------

Cancer Incidence Among Non-Saudi Population, 2020	61
--	----

PART V

INCIDENCE TABLES	64
-------------------------------	-----------

Table 5.1.1: Number of Cases Among Saudi Males by Primary Site and Age Groups, 2020	65
---	----

Table 5.1.2: Number of Cases Among Saudi Females by Primary Site and Age Groups, 2020	66
---	----

Table 5.1.3: Age-Specific Incidence Rate (AIR), Age Standardized Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site and Age groups, 2020.	67
--	----

Table 5.1.4: Age-Specific Incidence Rate (AIR), Age Standardized Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site and Age groups, 2020	68
--	----

Table 5.2.1: Number of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardized Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site, Age Groups and Regions 2020	69
--	----

Table 5.2.2: Number of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardized Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site, Age Groups, and Regions 2020	70
---	----

Table 5.2.3: Number of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardized Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site and Age.	71
---	----

TABLE OF CONTENTS

Table 5.2.4: Number of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardized Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site, Age Groups, and Regions 2020.	72	Table 5.4.2: Number of Cases Among Non-Saudi Females by Primary Site and Age Groups, 2020.	78
Table 5.3.1: Number of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardized Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site, Age Groups, and Regions 2020	73	Table 5.4.3: Age-Specific Incidence Rate (AIR), Age Standardized Incidence Rate (ASR) Among Non-Saudi Males (per 100,000) by Primary Site and Age groups, 2020.	79
Table 5.3.2: Number of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardized Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site, Age Groups, and Regions 2020	74	Table 5.4.4: Age-Specific Incidence Rate (AIR), Age Standardized Incidence Rate (ASR) Among Non-Saudi Females (per 100,000) by Primary Site and Age groups, 2020.	80
Table 5.3.3: Number of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardized Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site, Age Groups, and Regions 2020	75	Acknowledgment	81
Table 5.3.4: Number of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardized Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site and Age	76	Arabic Summary	84
Table 5.4.1: Number of Cases Among Non-Saudi Males by Primary Site and Age Groups, 2020.	77		



PART I

MATERIALS AND METHODS



BACKGROUND ON SAUDI ARABIA

Saudi Arabia is a vast country extending over four-fifths of the Arabian Peninsula. It stretches from the Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* square kilometers divided into 13 administrative regions Figure 1.1.



Figure 1.1: Administrative regions of Saudi Arabia.

The estimated population of Saudi Arabia in 2020 was 35013414. Saudi nationals were estimated to be 21430128 of these 10907568 (51%) were males and 10522560 (49%) were females.

The Non-Saudi population was 13583286 of these 9323857 (69%) were males and 4259429 (31%) were females. Figures 1.2 and 1.3 show the Saudi and Non-Saudi population pyramids by gender and age group respectively.

Figure 1.2: Population pyramid of Saudis (%) by gender and age group, 2020.





Figure 1.3: Population pyramid of non-Saudis (%) by gender and age group, 2020.



Saudi cancer registry.

The Saudi Cancer Registry (SCR) is a population-based registry. It is considered one of the first national registries in the Kingdom of Saudi Arabia. In 1992, it was established, funded by Ministry of Health in the King Faisal Specialist Hospital and Research Center in Riyadh; being the reference center for cancer care in the 90s named (National Cancer Registry) – The other health sectors that providing specialized cancer care : Armed Forces Hospital in Riyadh, National Guard Hospital in Riyadh, King Saud University Hospital, King Abdulaziz University Hospital, King Faisal University Hospital and Security Forces Hospital had participated in the preparation starting up of the registry. In 2005, The Ministry of Health joined the operators of specialized cancer care hospitals.

The National Cancer Registry name has been changed to the Saudi Cancer Registry and the new name appeared on the 2004 report. and it was accredited by the World Health Organization International Agency for Research on Cancer.

The statistical information provided by the Saudi Cancer Registry was significant for the

development of cancer prevention and care in Saudi Arabia during the past thirty years.

The Saudi Health Council decided - at 2014 to link the Saudi Cancer Registry to the Saudi Health Council due to the expansion and development of cancer care in all Saudi health sectors. The registry main office relocated to the headquarter of the Saudi Health Council.

The Saudi Cancer Registry collects data through oncology centers cancer registrars, most of all cancer cases are registered and their data is entered using a certified software. Data is processed and quality is managed, reviewed, and analyzed to generate the annual Saudi Cancer Registry reports.

Organizational structure.

The SCR consists of the main office which oversees data collection from all over the country through five regional offices to ensure full coverage of all healthcare facilities in the Kingdom as shown in Figure 1.4. The registry is supported by registry committee.

The committee provides scientific guidance to SCR, reviews cancer statistics reports, data requests, and provides help in disseminating reliable information; in addition to ensuring data confidentiality according to national and international guidelines.

Regional Offices.

Each of the SCR offices operates under a regional director who is responsible for the daily management. Staffing consists of senior and junior tumor registrars. SCR Main Office supervises regional offices to ensure accuracy and quality of data collected from

all regions. Quality control processes include verification of site, morphology, staging information, case linkage (tumor and patient), and consolidation of data. The Main Office also prepares annual reports for dissemination to the medical community, government departments, international organizations and the public.

Figure 1.4: Organizational Chart of the Saudi Cancer Registry.



Data management.

A royal decree has categorized cancer as a mandatory modifiable disease. This ensures the opportunity for comprehensive data collection. The SCR strives for full access to cancer data from all governmental and private hospitals, clinics, and laboratories throughout the Kingdom.

Cancer data are abstracted from patients' medical records based on clinical and/or histopathological diagnosis by SCR trained cancer registrars. Abstracted data includes personal identifications (name, ID number, gender, age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICD-O-3), published by the World Health Organization (WHO), 2000. Starting from the year 2001, changes were made in the coding of cancer types and behaviors as well as staging according to SEER Summary Stage 2000 to increase accuracy and consistency in stage coding. SEER Summary Stage Manual 2000 is available on the web

The cases diagnosed on or after 01 January 2008 were classified according to the updated ICD-O-3. While there have not been any changes in the primary site codes, there are significant changes regarding histology (cell types). Leukaemia and lymphoma are particularly affected. Some cases that were previously considered benign are now counted as malignant. Also, a small number of cancers that were previously coded as borderline tumors are now considered

benign. Counts of ovarian cancers, lymphoma, and leukaemia as well as some hematopoietic diseases will change due to changes in either the report's ability or definition. However, as with the SEER staging guidelines, the ICD-O changes reflect advances in the understanding of the pathology and behavior of cancers. It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes.

Since the WHO has not yet converted ICD-10 hematopoietic disease behavior changes, our software, CanReg 4.33 (developed by the International Agency for Research on Cancer (IARC), Lyon, France) cannot include these cases for analysis and they have been excluded. Every effort is made to accurately code patient and tumor information, to ensure that all data reviewed, linked, and consolidated, as appropriate, so that each malignancy is counted only once for statistical analysis. Data entry and incidence tables output were generated by CanReg software.

Notification.

This report covers data that were diagnosed between January and December 2020. Incident cases identified after this date (late reporting) will be reported in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as the case ascertainment processes have improved during the past years. Our aim is to reduce reporting lap between the year of diagnosis and the year of publishing the incidence report to a maximum of 2 years while maintaining high quality and completeness of data.

Definitions of Statistical Terms

Age-Specific Incidence Rate (AIR).

The number of cancer cases occurring during a specific period in a population of a specific age and gender group, divided by the number of midyear population of that age and gender group.

Age-Standardized Rate (ASR).

The age-standardized rate is a summary measure of the rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Standardized Incidence Rate. The rate is expressed per 100.000 population.

World Standard Population.

Age Class	Age Class
0 - 4	12.000
5 - 9	10.000
10 -14	9.000
15 -19	9.000
20 - 24	8.000
25 - 29	8.000
30 - 34	6.000
35 - 39	6.000
40 - 44	6.000
45 - 49	6.000
50 - 54	5.000
55 - 59	4.000
60 - 64	4.000
66 - 69	3.000
70 - 74	2.000
75 +	2.000
Total	100.000

*Doll R. Payne P. Waterhouse J. Cancer Incidence in Five Continents Vol. I. International Union against Cancer. 1966.

Crude Incidence Rate (CIR).

The crude incidence rate for a cancer site is the total number of cases registered as a proportion of the total population. It denotes the approximate number of cases occurring in every 100.000 individuals. All rates are thus, expressed as per 100.000 population. Cancer rates vary greatly with age and the crude rate is strongly influenced by the demographic structure of the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. It is not appropriate to compare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to assess time trends in registration data or compare incidence across geographical areas or between registries, it is necessary to first standardize the rates with respect to age.

Cumulative incidence rate.

The cumulative incidence rate is the probability or risk of individuals developing the disease during a specified period. For cancer, it is expressed as the number of newborn children (out of 100, or 1000) who would be expected to develop a particular cancer type before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age-standardized rate, it permits comparison between populations of different age structures. In this report, the age ranges between 0 to 64 and 0 to 74 are used. The cumulative rate is the summation of the cancer age-specific rates, which are computed for five-year age intervals.

ICD-10.

The World Health Organization's International Classification of Diseases, tenth edition..

ICD-O-3.

The World Health Organization's International Classification of Diseases for Oncology, 3rd Edition has been the standard coding system for neoplasms for over 25 years. The coding system includes a four-character code for the primary site, a four-digit numeric code for cell type, a one-digit code for behavior, and a one-digit code for tumor aggressiveness (grade).

Incidence rate.

An incidence rate is defined as the rate at which a new event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined period, divided by the population at risk of developing that disease.

Mean.

The simple mathematical average of two or more numbers.

Median.

The midpoint of the range numbers that are arranged in order of value.

Metastasis.

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal, and or visceral organs.

Range.

It is the difference between the maximum and minimum values in a set of observations.

Rank.

This measure reflects the importance of a specific cancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency.

Ratio.

It is the relation between two quantities. The first quantity is a numerator and the second is a denominator.

Relative frequency.

This statistic is defined as the number of specific cancer cases registered relative to the total number of all cancer. It is expressed as a percentage.

Summary Stage.

Staging is the grouping of cancer cases into broad categories based on the extent of the disease.

PART II

OVERVIEW OF CANCER INCIDENCE 2020



Cancer incidence in Saudi Arabia, 2020.

Between January 01 and December 31, 2020, the total number of newly diagnosed cancer cases reported to the Saudi Cancer Registry (SCR) was 17631. Overall cancer was more among women than men; it affected 8056 (45.7%) males and 9575 (54.3%) females. A total of 14235 cases were reported among Saudi nationals, 3274 among non-Saudis, and 122 of unknown nationalities.

A total of 17291 cases were analyzed, of which 14050 (81.3%) were Saudi nationals and 3241 (18.7%) were non-Saudis.

A total of 340 cases were excluded from the analysis: 122 cases of them were unknown nationalities, and 218 cases failed to be converted to ICD-10 codes. The software (CanReg-4) does not include in situ cases in the statistical analysis, Table 2.1.

Among Saudis 6209 (44.2%) were males and 7841 (55.8%) were females with a male to female ratio of 100 to 126. The crude incidence rates (CIR) of all cancers were 56.8/100,000 in males and 74.4/100,000 in females.

The overall age-standardized incidence rate (ASR) was 74.7/100,000 in males and 92.1/100,000 in females.

Eastern region reported the highest ASR among males 114.6/100,000 and Riyadh region for females 153.5 /100,000, whereas, Jazan region reported the lowest ASR among males and females (38.4 /100,000 and 36.9/100,000 for males and females respectively), Table 2.2 and Figure 2.1.

Table 2.1: Distribution of analyzed and non-analyzed cancer cases reported to Saudi Cancer Registry by nationality and gender, 2020.


Saudis						Unknown Nationality			Non-Saudis					
Analyzed			Non-Analyzed						Analyzed			Non-Analyzed		
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
6209	7841	14050	90	95	185	70	52	122	1669	1572	3241	18	15	33

Table 2.2: Distribution of cancer cases among Saudi nationals by regions, 2020.

Region	Male	%	ASR	Female	%	ASR	All	%
Riyadh	1903	30.6	106.2	2590	33.0	153.5	4493	32.0
Makkah	1279	20.6	63.7	1570	20.0	78.5	2849	20.3
Eastern	1241	20.0	114.6	1458	18.6	125.5	2699	19.2
Asir	365	5.9	47.2	414	5.3	50	779	5.5
Madinah	337	5.4	58.9	430	5.5	74.8	767	5.5
Qassim	254	4.1	60.5	338	4.3	78.9	592	4.2
Tabuk	180	2.9	73.2	238	3.0	84.4	418	3.0
Jazan	179	2.9	38.4	197	2.5	36.9	376	2.7
Hail	101	1.6	43.1	172	2.2	67.7	273	1.9
Najran	125	2.0	80.2	141	1.8	76.9	266	1.9
Jouf	92	1.5	65.8	117	1.5	82.6	209	1.5
Baha	82	1.3	44.6	91	1.2	43.7	173	1.2
Northern	68	1.1	60.4	80	1.0	67.3	148	1.1
Unknown	2	0.0	-	3	0.0	-	5	0.0
International	1	0.0	-	2	0.0	-	3	0.0
Total	6209	100.0	-	7841	100.0	-	14050	100.0


**Unknown nationalities, in situ, and ICD-10 conversion failure are excluded from the analysis.

Figure 2.1: Age-Standardized Rate (ASR)* of all cancer sites among Saudi nationals, 2020.



The age-specific incidence rate (AIR) increased with advancing age in both genders. The median age at diagnosis was 57 with a range of 0-116 for males, and 51 with a range of 0-116 for females, Figure 2.2.

Figure 2.2: Age-Specific Incidence Rate (AIR) for all cancer among Saudis, 2020.



Confirmation of malignancy was based mainly on histopathology reports (91%), followed by Cytology and Hematological (4%), then Histology of metastases (2%), then Unknown (1%). Other sources such as Clinical, Laboratory tests and Medical Imaging were the source that is about (1.2%), Table 2.3.

Table 2.3: Basis of diagnosis of cancer cases, 2020.

Basis of Diagnosis	No	%
Histology of primary	12762	91
Cytology/Haematological	500	4
Histology of metastases	273	2
Unknown	270	2
Medical Imaging	204	1
Clinical	35	0.2
Laboratory tests	6	0.0
Total	14050	100

Cancer Distribution among Saudi Nationals, 2020.

In females, the highest number of cancer cases was reported for the age group (45-59), with a total of 2731 (35.0%) cancer cases. Whereas, in males, the highest number of cases was reported for the age group (60-74), with a total of 1800 (29.2%) cancer cases Figure 2.3.

Figure 2.3: Distribution of cancer cases among Saudi nationals by gender and age groups, 2020.





Figure 2.4: Distributions of the most frequent types of cancer among Saudi nationals by gender and age groups, 2020.








Table 2.4: Most common cancers among Saudi nationals, 2020.

Sites	No.	%
Breast	2499	17.8
Colorectal	1729	12.3
Thyroid	1044	7.4
Leukaemia	835	5.9
NHL	756	5.4
Hodgkin' lymphoma	581	4.1
Corpus Uteri	494	3.5
Brain, CNS	488	3.5
Lung	458	3.3
Liver	450	3.2

Table 2.5: Most common cancers among Saudi nationals by gender, 2020.

Male	6209	%	Female	7841	%
Colorectal	966	15.6	Breast	2459	31.4
Leukaemia	494	8.0	Thyroid	816	10.4
NHL	420	6.8	Colorectal	763	9.7
Prostate	366	5.9	Corpus Uteri	494	6.3
Lung	353	5.7	Leukaemia	341	4.3
Hodgkin's lymphoma	347	5.6	NHL	336	4.3
Liver	291	4.7	Ovary	234	3.0
Bladder	291	4.7	Hodgkin's lymphoma	234	3.0
Brain, CNS	283	4.6	Brain, CNS	205	2.6
Kidney	228	3.7	Liver	159	2.0

Table 2.6: Number, percentage, CIR, ASR, and cumulative rates (per 100,000) among Saudi nationals by primary cancer site and gender, 2020.

ICD-10	Site	Male						Female					
		No.	%	Crude Rate	ASR World	Cumulative Rate		No.	%	Crude Rate	ASR World	Cumulative Rate	
						0 - 64	0 - 74					0 - 64	0 - 74
All	All sites Total	6209	%100	56.8	74.7	209.40	262.75	7841	%100	74.4	92.1	308.20	359.15
Not C44	All sites but C44	6087	%98.00	55.7	73.1	206.70	258.55	7753	%98.90	73.5	91	306.40	356.45
C00	Lip	14	%0.20	0.1	0.2	0.35	0.45	8	%0.10	0.1	0.1	0.15	0.25
C01-C02	Tongue	62	%1.00	0.6	0.8	2.40	2.90	58	%0.70	0.6	0.8	2.10	2.45
C03-C06	Mouth	68	%1.10	0.6	0.9	1.65	2.55	40	%0.50	0.4	0.5	1.15	1.55
C07-C08	Salivary glands	23	%0.40	0.2	0.2	0.90	1.05	12	%0.20	0.1	0.1	0.45	0.60
C09	Tonsil	4	%0.10	0	0	0.20	0.20	3	%0.00	0	0	0.15	0.15
C10	Other Oropharynx	5	%0.10	0	0.1	0.20	0.25	0	%0.00	0	0	0.00	0.00
C11	Nasopharynx	139	%2.20	1.3	1.5	6.00	6.65	57	%0.70	0.5	0.6	2.50	2.75
C12-C13	Hypopharynx	6	%0.10	0.1	0.1	0.05	0.20	6	%0.10	0.1	0.1	0.25	0.30
C14	Pharynx unspec.	2	%0.00	0	0	0.00	0.00	5	%0.10	0	0.1	0.25	0.25
C15	Oesophagus	76	%1.20	0.7	1	1.75	2.80	32	%0.40	0.3	0.4	0.70	1.00
C16	Stomach	164	%2.60	1.5	2.1	4.70	6.60	125	%1.60	1.2	1.5	4.15	5.15
C17	Small intestine	50	%0.80	0.5	0.6	1.75	2.00	27	%0.30	0.3	0.4	0.80	1.00
C18	Colon	597	%9.60	5.5	7.6	18.90	24.95	519	%6.60	4.9	6.5	18.10	22.50
C19-C20	Rectum	369	%5.90	3.4	4.8	11.90	15.80	244	%3.10	2.3	3.1	7.95	10.00
C21	Anus	26	%0.40	0.2	0.4	0.75	1.20	12	%0.20	0.1	0.2	0.35	0.45
C22	Liver	291	%4.70	2.7	4	6.60	10.55	159	%2.00	1.5	2.2	3.75	6.45
C23-C24	Gallbladder etc.	77	%1.20	0.7	1	2.45	3.30	89	%1.10	0.8	1.2	2.70	3.70
C25	Pancreas	226	%3.60	2.1	3	6.90	9.70	131	%1.70	1.2	1.8	3.85	5.35
C30-C31	Nose, sinuses etc.	33	%0.50	0.3	0.4	1.20	1.50	18	%0.20	0.2	0.2	0.75	0.90
C32	Larynx	72	%1.20	0.7	1	2.10	2.75	7	%0.10	0.1	0.1	0.15	0.25
C33-C34	Trachea, Bronchus, Lung	353	%5.70	3.2	4.8	9.10	13.45	105	%1.30	1	1.4	3.30	4.45
C37-C38	Other Thoracic organs	35	%0.60	0.3	0.4	1.30	1.55	23	%0.30	0.2	0.2	1.00	1.00
C40-C41	Bone	132	%2.10	1.2	1.2	6.00	6.30	91	%1.20	0.9	0.9	4.25	4.45
C43	Melanoma of Skin	13	%0.20	0.1	0.2	0.45	0.50	8	%0.10	0.1	0.1	0.30	0.35
C44	Other Skin	122	%2.00	1.1	1.6	2.70	4.20	88	%1.10	0.8	1.1	1.80	2.70
C45	Mesothelioma	10	%0.20	0.1	0.1	0.20	0.25	3	%0.00	0	0	0.10	0.10
C46	Kaposi sarcoma	22	%0.40	0.2	0.3	0.50	0.65	6	%0.10	0.1	0.1	0.25	0.25
C47;C49	Connective, Soft tissue	99	%1.60	0.9	1	4.40	4.80	86	%1.10	0.8	0.9	3.90	4.25
C50	Breast	40	%0.60	0.4	0.5	1.50	1.80	2459	%31.40	23.3	28.4	105.20	116.65
C51	Vulva	-	-	-	-	-	-	16	%0.20	0.2	0.2	0.70	0.70
C52	Vagina	-	-	-	-	-	-	5	%0.10	0	0.1	0.10	0.20
C53	Cervix Uteri	-	-	-	-	-	-	135	%1.70	1.3	1.6	5.40	6.25
C54	Corpus Uteri	-	-	-	-	-	-	494	%6.30	4.7	6.9	14.80	22.05
C55	Uterus unspec.	-	-	-	-	-	-	118	%1.50	1.1	1.6	3.75	5.50
C56	Ovary	-	-	-	-	-	-	234	%3.00	2.2	2.8	9.40	10.95
C57	Other Female Genital	-	-	-	-	-	-	34	%0.40	0.3	0.5	0.95	1.40
C58	Placenta	-	-	-	-	-	-	0	%0.00	0	0	0.00	0.00
C60	Penis	1	%0.00	0	0	0.00	0.00	-	-	-	-	-	-
C61	Prostate	366	%5.90	3.3	5.2	5.55	11.65	-	-	-	-	-	-
C62	Testis	147	%2.40	1.3	1.2	7.30	7.30	-	-	-	-	-	-
C63	Other male genital	1	%0.00	0	0	0.05	0.05	-	-	-	-	-	-
C64	Kidney	228	%3.70	2.1	2.8	8.50	10.10	150	%1.90	1.4	1.8	5.95	6.95
C65	Renal Pelvis	9	%0.10	0.1	0.1	0.40	0.45	0	%0.00	0	0	0.00	0.00
C66	Ureter	5	%0.10	0	0.1	0.05	0.15	0	%0.00	0	0	0.00	0.00
C67	Bladder	291	%4.70	2.7	3.9	7.50	10.55	57	%0.70	0.5	0.7	1.45	2.20
C68	Other Urinary organs	13	%0.20	0.1	0.2	0.45	0.55	1	%0.00	0	0	0.05	0.05
C69	Eye	20	%0.30	0.2	0.2	0.80	0.85	18	%0.20	0.2	0.2	0.85	0.90
C70-C72	Brain, Nervous system	283	%4.60	2.6	3	12.15	13.25	205	%2.60	1.9	2.2	9.45	10.15
C73	Thyroid	228	%3.70	2.1	2.4	9.45	10.55	816	%10.40	7.7	8.1	37.75	39.70
C74	Adrenal gland	16	%0.30	0.1	0.1	0.80	0.80	21	%0.30	0.2	0.2	0.90	1.05
C75	Other Endocrine	4	%0.10	0	0	0.20	0.20	5	%0.10	0	0	0.25	0.25
C81	Hodgkin disease	347	%5.60	3.2	3.3	15.95	16.75	234	%3.00	2.2	2.2	11.20	11.50
C82-C85;C96	Non-Hodgkin lymphoma	420	%6.80	3.8	4.6	16.10	18.80	336	%4.30	3.2	3.9	12.50	14.80
C88	Immunoproliferative dis.	0	%0.00	0	0	0.00	0.00	1	%0.00	0	0	0.05	0.05
C90	Multiple Myeloma	94	%1.50	0.9	1.2	2.90	3.80	70	%0.90	0.7	0.9	2.50	3.25
C91	Lymphoid Leukaemia	150	%2.40	1.4	1.7	5.80	6.75	84	%1.10	0.8	0.9	3.80	4.10
C92-C94	Myeloid Leukaemia	210	%3.40	1.9	2.3	8.45	9.80	156	%2.00	1.5	1.7	6.85	7.35
C95	Leukaemia unspec.	134	%2.20	1.2	1.3	6.25	6.55	101	%1.30	1	1.1	4.50	4.90
Other	Other & unspecified	112	%1.80	1	1.4	3.85	4.95	129	%1.60	1.2	1.6	4.70	5.65

Cancer incidence among adults (>14 years), 2020.

Between January and December 2020, the total number of cancer incidence cases reported to the Saudi cancer registry among adults aged above 14 was 16510. Among those, 13378 cancer cases were Saudis and 3016 were non-Saudis, and unknown nationalities were reported in 116 cases. A total of 7404 (44.8%) cases were males and 9106 (55.2%) were females with a male to female ratio of 100 to 123, Table 2.7.1.

Table 2.7.1: Distribution of analyzed and non-analyzed adult cancer cases reported to Saudi cancer registry by nationality and gender, 2020.

Saudis						Unknown Nationality			Non-Saudis					
Analyzed			Non-Analyzed						Analyzed			Non-Analyzed		
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
5715	7485	13200	85	93	178	67	49	116	1519	1465	2984	18	14	32

Table 2.7.2: Most common cancers among Saudi adults, 2020.

Sites	No.	%
Breast	2484	18.8
Colorectal	1710	13.0
Thyroid	1032	7.8
NHL	709	5.4
Leukaemia	599	4.5
Corpus Uteri	494	3.7
Lung	453	3.4
Hodgkin's lymphoma	451	3.4
Liver	440	3.3
Prostate	362	2.7

Table 2.7.3: Top ten cancers reported among Saudi adults by gender, 2020.

Male	5715	%	Female	7485	%
Colorectal	956	16.7	Breast	2444	32.7
NHL	387	6.8	Thyroid	808	10.8
Prostate	362	6.3	Colorectal	754	10.1
Leukaemia	353	6.2	Corpus Uteri	494	6.6
Lung	349	6.1	NHL	322	4.3
Liver	285	5.0	Leukaemia	246	3.3
Bladder	285	5.0	Ovary	223	3.0
Hodgkin's lymphoma	266	4.7	Hodgkin's lymphoma	185	2.5
Pancreas	225	3.9	Brain, CNS	160	2.1
Thyroid	224	3.9	Liver	155	2.1

Childhood cancers reported to the Saudi cancer registry (≤ 14 years), 2020.

A total of 970 cancer cases were diagnosed among children aged between 0 and 14 accounting for 5.5% of the total number of cancers reported to the Saudi cancer registry in 2020. The reported incidents show that cancer was more common among boys than girls, 570 (58.7 %) cases were reported among boys and 400 (41.3%) were reported among girls. A total of 773 cancer cases were reported among Saudi children, 191 were among non-Saudis, and 6 cases were of unknown nationalities. The total number of analyzed cases was 956 including 766 Saudis and 190 non-Saudis. Among Saudis, 451 (58.9 %) were boys and 315 (41.1 %) were girls, Table 2.8.1.

Table 2.8.1: Distribution of reported childhood cancer in Saudi Arabia by nationality and gender, 2020.

Saudis						Unknown Nationality			Non-Saudis					
Analyzed			Non-Analyzed						Analyzed			Non-Analyzed		
Boys	Girls	Total	Boys	Girls	Total	Boys	Girls	Total	Boys	Girls	Total	Boys	Girls	Total
451	315	766	5	2	7	3	3	6	111	79	190	0	1	1

Childhood cancers accounted for 5.4% of all cancer among Saudis. The leading cancer among Saudi children was leukaemia (30.8%), followed by Brain, CNS (16.7 %), then Hodgkin's lymphoma (16.3 %), and Bone (6.8%), Table 2.8.2.

Table 2.8.2: Top ten cancers among Saudi children, 2020.

Sites	No.	%
Leukaemia	236	30.8
Brain, CNS	128	16.7
Hodgkin's lymphoma	125	16.3
Bone	52	6.8
NHL	39	5.1
Kidney	33	4.3
Connective,Soft tissue	24	3.1
Eye	23	3.0
Adrenal gland	23	3.0
Ovary	11	1.4

Table 2.8.3: Distribution of top ten Childhood cancer sites by genders, 2020.

Male	451	%	Female	315	%
Leukaemia	141	31.3	Leukaemia	95	30.2
Brain, CNS	84	18.6	Hodgkin's lymphoma	47	14.9
Hodgkin's lymphoma	78	17.3	Brain, CNS	44	14.0
Bone	33	7.3	Bone	19	6.0
NHL	29	6.4	Kidney	17	5.4
Kidney	16	3.5	Eye	12	3.8
Connective,Soft tissue	13	2.9	Connective,Soft tissue	11	3.5
Adrenal gland	12	2.7	Ovary	11	3.5
Eye	11	2.4	Adrenal gland	11	3.5
Liver	6	1.3	NHL	10	3.2

Table 2.8.4: Distribution of morphological types for the most common cancers reported among Saudi children by gender, 2020.

Primary Site	Code	Morphology	Male	%	Female	%
Leukaemia	98003	Leukaemia, NOS	64	45.4	43	45.3
	98263	Burkitt cell leukaemia	20	14.2	13	13.7
	98613	Acute myeloid leukaemia, NOS	20	14.2	10	10.5
	98363	Precursor B-cell lymphoblastic leukaemia	12	8.5	7	7.4
	98373	Precursor T-cell lymphoblastic leukaemia	9	6.4	7	7.4
	98013	Acute leukemia, NOS	6	4.3	4	4.2
	98663	Acute promyelocytic leukaemia, t(17;15)(q22;q12-11)	3	2.1	2	2.1
	98353	Precursor cell lymphoblastic leukaemia, NOS	3	2.1	2	2.1
	98913	Acute monocytic leukaemia	-	0.0	2	2.1
	98973	Acute myeloid leukaemia, 11q23 abnormalities	1	0.7	1	1.1
		Others	3	2.1	4	4.2
		Total	141	100.0	95	100.0
Brain, CNS	94703	Medulloblastoma, NOS	25	27.5	11	23.4
	93803	Glioma, malignant	21	23.1	14	29.8
	80003	Neoplasm, malignant	10	11.0	3	6.4
	94003	Astrocytoma, NOS	7	7.7	3	6.4
	Total	Astrocytoma, NOS	7	7.7	3	6.4
	93913	Ependymoma, NOS	4	4.4	3	6.4
	94403	Glioblastoma, NOS	3	3.3	2	4.3
	95003	Neuroblastoma, NOS	5	5.5	-	0.0
	90643	Germinoma	2	2.2	1	2.1
	94203	Fibrillary astrocytoma	2	2.2	1	2.1
		Others	5	5.5	6	12.8
		Total	91	100.0	47	100.0
Hodgkin's lymphoma	96503	Hodgkin lymphoma, NOS	51	65.4	33	70.2
	96633	Hodgkin lymphoma, nodular sclerosis, NOS	12	15.4	9	19.1
	96593	Hodgkin lymphoma, nodular lymphocyte predominance	9	11.5	2	4.3
	96523	Hodgkin lymphoma, mixed cellularity, NOS	5	6.4	3	6.4
	96513	Hodgkin lymphoma, lymphocyte-rich	1	1.3	-	0.0
		Total	78	100.0	47	100.0

Primary Site	Code	Morphology	Male	%	Female	%
Bone	92603	Ewing sarcoma	11	33.3	12	63.2
	91803	Osteosarcoma, NOS	12	36.4	4	21.1
	88003	Sarcoma, NOS	4	12.1	1	5.3
	89003	Rhabdomyosarcoma, NOS	2	6.1	-	0.0
	92613	Adamantinoma of long bones	1	3.0	-	0.0
	88303	Malignant fibrous histiocytoma	-	0.0	1	5.3
	80033	Malignant tumor, giant cell type	1	3.0	-	0.0
	80003	Neoplasm, malignant	1	3.0	-	0.0
	88033	Small cell sarcoma	-	0.0	1	5.3
	90403	Synovial sarcoma, NOS	1	3.0	-	0.0
		Total	33	100.0	19	100.0
NHL	96873	Burkitt lymphoma, NOS	11	37.9	2	20.0
	96803	Malignant lymphoma, large B-cell, diffuse, NOS	8	27.6	4	40.0
	95903	Malignant lymphoma, NOS	3	10.3	1	10.0
	95913	Malignant lymphoma, non-Hodgkin, NOS	2	6.9	1	10.0
	97543	Langerhans cell histiocytosis, disseminated	1	3.4	1	10.0
	97023	Mature T-cell lymphoma, NOS	2	6.9	-	0.0
	97143	Anaplastic large cell lymphoma, T cell and Null cell type	1	3.4	-	0.0
	96903	Follicular lymphoma, NOS	1	3.4	-	0.0
	97003	Mycosis fungoides	-	0.0	1	10.0
	Total	29	100.0	10	100.0	
Kidney	89603	Nephroblastoma, NOS	13	81.3	15	88.2
	89643	Clear cell sarcoma of kidney	2	12.5	1	5.9
	83123	Renal cell carcinoma, NOS	1	6.3	1	5.9
		Total	16	100.0	17	100.0
Connective Tissue	89003	Rhabdomyosarcoma, NOS	4	30.8	3	27.3
	89103	Embryonal rhabdomyosarcoma, NOS	2	15.4	1	9.1
	95003	Neuroblastoma, NOS	2	15.4	1	9.1
	88013	Spindle cell sarcoma	-	0.0	2	18.2
	88043	Epithelioid sarcoma	-	0.0	1	9.1
	88103	Fibrosarcoma, NOS	1	7.7	-	0.0
	95403	Malignant peripheral nerve sheath tumor	1	7.7	-	0.0
	89633	Malignant rhabdoid tumor	1	7.7	-	0.0
	88003	Sarcoma, NOS	1	7.7	-	0.0
	88033	Small cell sarcoma	-	0.0	1	9.1
		Others	1	7.7	2	18.2
	Total	13	100.0	11	100.0	

Primary Site	Code	Morphology	Male	%	Female	%
Eye	95103	Retinoblastoma, NOS	9	81.8	6	50.0
	95123	Retinoblastoma, undifferentiated	1	9.1	5	41.7
	80003	Neoplasm, malignant	1	9.1	1	8.3
		Total	11.0	100	12.0	100.0
Adrenal gland	95003	Neuroblastoma, NOS	5	41.7	6	54.5
	83703	Adrenal cortical carcinoma	4	33.3	5	45.5
	94903	Ganglioneuroblastoma	2	16.7	-	0.0
	89633	Malignant rhabdoid tumor	1	8.3	-	0.0
		Total	12	100.0	11	100.0
Ovary	90603	Dysgerminoma	-	-	3	27.3
	90853	Mixed germ cell tumor	-	-	2	18.2
	90713	Yolk sac tumor	-	-	2	18.2
	91003	Choriocarcinoma, NOS	-	-	1	9.1
	84413	Serous cystadenocarcinoma, NOS	-	-	1	9.1
	90803	Teratoma, malignant, NOS	-	-	1	9.1
	90801	Teratoma, NOS	-	-	1	9.1
		Total	-	-	11	100.0

Distribution of cancer cases in the 13 administrative regions of Saudi Arabia, 2020.

The following bar charts show the distribution of the most common cancer sites in the 13 administrative regions of Saudi Arabia by gender. These sites are listed based on the total number of cases for each site reported by the permanent address (region) of the patient at the time of diagnosis. In most regions breast and thyroid cancers were the leading cancers among women, while colorectal cancer and NHL were the leading cancers among men. It is worth noting that Riyadh, Makkah, and Eastern Province represent the majority of cases. Also, its worth noting that among males mouth cancer and Tongue cancer in Jazan region ranked among the top ten.

Figure 2.5.1: Riyadh Region, 2020 (Relative Frequency Distribution).




Figure 2.5.2: Makkah Region, 2020 (Relative Frequency Distribution).




Figure 2.5.3: Eastern Region, 2020 (Relative Frequency Distribution).




Figure 2.5.4: Madinah Region, 2020 (Relative Frequency Distribution).




Figure 2.5.5: Northern Region, 2020 (Relative Frequency Distribution).




Figure 2.5.6: Qassim Region, 2020 (Relative Frequency Distribution).




Figure 2.5.7: Jazan Region, 2020 (Relative Frequency Distribution).




Figure 2.5.8: Hail Region, 2020 (Relative Frequency Distribution).




Figure 2.5.9: Najran Region, 2020 (Relative Frequency Distribution).




Figure 2.5.10: Baha Region, 2020 (Relative Frequency Distribution).




Figure 2.5.11: Asir Region, 2020 (Relative Frequency Distribution).




Figure 2.5.12: Tabuk Region, 2020 (Relative Frequency Distribution).





Figure 2.5.13: Jouf Region, 2020 (Relative Frequency Distribution).



International comparison of age-standardized incidence rates.

Figure 2.6.1: Comparison of ASR* for Saudi males with selected countries**





Figure 2.6.2: Comparison of ASR* for Saudi females with selected countries**



**Source for this information is summarized on page 58.



PART III

INCIDENCE OF MOST COMMON CANCERS DIAGNOSED AMONG SAUDI NATIONALS 2020



Cancer incidence for most common sites among Saudi nationals, 2020.

This section demonstrates the most common cancers diagnosed among Saudi nationals during the period between January and December 2020. It shows the distribution of the most common cancers by gender and geographical area. Data presented as absolute numbers, relative frequency, and incidence rates. It also presents comparisons of cancer incidence among Saudis with cancer incidence reported from selected developed and developing countries.

Table 3.1: Most common cancer among Saudis by gender, 2020.

Sites	Male	Female	All	%
Breast	40	2459	2499	17.8
Colorectal	966	763	1729	12.3
Thyroid	228	816	1044	7.4
Leukaemia	494	341	835	5.9
NHL	420	336	756	5.4
Hodgkin's lymphoma	347	234	581	4.1
Corpus Uteri	-	494	494	3.5
Brain, CNS	283	205	488	3.5
Lung	353	105	458	3.3
Liver	291	159	450	3.2

Female breast cancer (C50).

Breast cancer was ranked first among Saudi females. There were 2459 female breast cancer cases. Breast cancer accounted for 17.8% of all cancers reported among Saudi nationals, and 31.4% of all cancers reported among females. The ASR was 28.4/100,000 for the Saudi female population. The five regions with the highest ASR per 100,000 population were Eastern region at 46.2/100,000, followed by Riyadh with 43.3/100,000, Qassim with 28.1/100,000, Jouf with 25.2/100,000 and Makkah region with 24.9/100,000 (Figure 3.1.3). The median age at diagnosis was 51 years (ranging between 20 and 95).

Figure 3.1.1: Age-Specific Incidence Rate (AIR) for breast cancer among Saudi females, 2020.




Table 3.1.1: Morphological distribution of breast cancer among Saudi females, 2020.

ICD-O-3	Morphology	Female	%
85003	Infiltrating duct carcinoma, NOS	1968	80.0
85203	Lobular carcinoma, NOS	190	7.7
80103	Carcinoma, NOS	74	3.0
80003	Neoplasm, malignant	64	2.6
85223	Infiltrating duct and lobular carcinoma	37	1.5
85213	Infiltrating ductular carcinoma	27	1.1
81403	Adenocarcinoma, NOS	11	0.4
90203	Phyllodes tumor, malignant	11	0.4
85233	Infiltrating duct mixed with other types of carcinoma	10	0.4
85753	Metaplastic carcinoma, NOS	10	0.4
	Others	57	2.3
Total		2459	100.0

Figure 3.1.2: Stage distribution of breast cancer among Saudi females, 2020.




Figure 3.1.3: Regional distribution of breast cancer (ASR*) among Saudi females, 2020.





Figure 3.1.4: Comparison of ASR* for Saudi females breast cancer with selected countries.



**Source for this information is summarized on page 58.

Colorectal cancer (C18-C20).

Colorectal cancer was ranked first among Saudi males and third among Saudi females. There were 1729 cases of colorectal cancer accounting for 12.3% of all newly diagnosed cases in the year 2020 among Saudi nationals. It affected 966 (55.9%) males and 763 (44.1%) females with a male to female ratio of 126 to 100. The ASR was 12.4/100,000 for males and 9.6/100,000 for females. The five regions with the highest ASR in males were Riyadh at 18.3/100,000 Eastern region at 16.1/100,000, followed by Qassim at 11.7/100,000, then Tabuk at 11.4/100,000, and Makkah at 11.3/100,000. In females, regions with the highest ASR were Riyadh at 16.5/100,000, followed by Qassim at 12.5/100,000, then Eastern region at 12.1/100,000, then Makkah at 9.2/100,000, and Jouf at 9/100,000 (Figure 3.2.3). The median age at diagnosis was 60 years in males (ranging between 17 and 98) and 58 years in females (ranging between 20 and 98).

Figure 3.2.1: Age-Specific Incidence Rate (AIR) for colorectal cancer among Saudi nationals, 2020.




Table 3.2.1: Morphological distribution of colorectal cancer among Saudi nationals, 2020.

ICD-O-3	Morphology	Male	%	Female	%
81403	Adenocarcinoma, NOS	843	87.3	659	86.4
84803	Mucinous adenocarcinoma	47	4.9	32	4.2
80003	Neoplasm, malignant	20	2.1	16	2.1
80103	Carcinoma, NOS	14	1.4	9	1.2
84903	Signet ring cell carcinoma	9	0.9	8	1.0
82633	Adenocarcinoma in tubulovillous adenoma	7	0.7	6	0.8
82463	Neuroendocrine carcinoma, NOS	5	0.5	7	0.9
82103	Adenocarcinoma in adenomatous polyp	4	0.4	1	0.1
80703	Squamous cell carcinoma, NOS	3	0.3	4	0.5
84813	Mucin-producing adenocarcinoma	3	0.3	3	0.4
	Other	11	1.1	18	2.4
Total		966	100.0	763	100.0

Figure 3.2.2: Stage distribution of colorectal cancer among Saudi nationals, 2020.




Figure 3.2.3: Regional distribution of colorectal cancer (ASR*) among Saudi nationals, 2020.





Figure 3.2.4: Comparison of ASR* for colorectal cancer among Saudis with ASR in selected countries**



**Source for this information is summarized on page 58.

Thyroid cancer (C73).

Thyroid cancer was ranked second among Saudi females and tenth among Saudi males. There were 1044 thyroid cases of cancer accounting for 7.4% of all newly diagnosed cancers in 2020 among Saudi nationals. Thyroid cancer affected 816 (78.2%) females and 228 (21.8%) males, with a female to male ratio of 358 to 100. The ASR was 8.1/100,000 for females and 2.4/100,000 for males. The five regions with the highest ASR for females were Riyadh Region at 15.8/100,000, followed by Najran at 15.5/100,000, then Hail at 14.6/100,000, then Tabuk at 13.2/100,000, then Eastern Region at 9.7/100,000. In males, regions with the highest ASR were Najran at 5.6 /100,000, followed by Northern region at 4.6/100,000, Eastern Region at 4.1/100,000, then Riyadh at 3.9 /100,000, and Qassim both at 3.3/100,000 (Figure 3.3.3). The median age at diagnosis was 42 years in females (ranging between 11 and 84) and 46 years in males (ranging between 5 and 89).

Figure 3.3.1: Age-Specific Incidence Rate (AIR) for thyroid cancer among Saudi nationals, 2020.




Table 3.3.1: Morphological distribution of thyroid cancer among Saudi nationals, 2020.

ICD-O-3	Morphology	Male	%	Female	%
82603	Papillary adenocarcinoma, NOS	107	46.9	363	44.5
80503	Papillary carcinoma, NOS	39	17.1	197	24.1
83413	Papillary microcarcinoma	20	8.8	88	10.8
83403	Papillary carcinoma, follicular variant	22	9.6	62	7.6
83303	Follicular adenocarcinoma, NOS	3	1.3	22	2.7
82903	Oxyphilic adenocarcinoma	6	2.6	14	1.7
80003	Neoplasm, malignant	6	2.6	13	1.6
80103	Carcinoma, NOS	11	4.8	11	1.3
83433	Papillary carcinoma, encapsulated		0.0	11	1.3
83353	Follicular carcinoma, minimally invasive	2	0.9	9	1.1
	Others	12	5.3	26	3.2
Total		228	100.0	816	100.0

Figure 3.3.2: Stage distribution of thyroid cancer among Saudi nationals, 2020.




Figure 3.3.3: Regional distribution of thyroid cancer (ASR*) among Saudi nationals, 2020.





Figure 3.3.4: Comparison of ASR* for thyroid cancer among Saudis with ASR in selected countries**



**Source for this information is summarized on page 58.

Leukaemia (C91-C95).

Leukaemia was ranked second among Saudi males and the fifth among Saudi females. There were 835 cases accounting for 5.9% of all cancer cases diagnosed among Saudi nationals in 2020. Leukaemia affected 494 (59.2%) males and 341 (40.8%) females with a male to female ratio of 145 to 100. The ASR was 5.3/100,000 for males and 3.7/100,000 for females. The five regions with the highest ASR in males were Jouf at 8.1/100,000, followed by Riyadh at 7.9/100,000, and Eastern region and Tabuk both at 7.5/100,000, then Najran at 6.9/100,000. In females, regions with the highest ASR were Northern region at 9.5/100,000, then Madinah at 6.7/100,000, then Riyadh at 5.4/100,000, then Najran at 5/100,000, and Eastern region at 4.3/100,000 (Figure 3.4.2). The median age at diagnosis was 36 years in males (ranging between 0 and 91) and 32 years in females (ranging between 0 and 89).

Figure 3.4.1: Age-Specific Incidence Rate (AIR) for leukaemia among Saudi nationals, 2020.




Table 3.4.1: Morphological distribution of leukaemia among Saudi nationals, 2020.

Code	Morphology	Male	%	Female	%
98003	Leukaemia, NOS	114	23.1	88	25.8
98613	Acute myeloid leukaemia, NOS	99	20.0	60	17.6
98633	Chronic myeloid leukaemia, NOS	64	13.0	41	12.0
98233	B-cell chronic lymphocytic leukaemia/small lymphocytic lymphom	57	11.5	20	5.9
98263	Burkitt cell leukaemia	30	6.1	25	7.3
98363	Precursor B-cell lymphoblastic leukaemia	27	5.5	16	4.7
98013	Acute leukaemia, NOS	20	4.0	13	3.8
98373	Precursor T-cell lymphoblastic leukaemia	18	3.6	14	4.1
98663	Acute promyelocytic leukaemia, t(17;15)(q22;q12-11)	13	2.6	13	3.8
98353	Precursor cell lymphoblastic leukaemia, NOS	9	1.8	5	1.5
	Others	43	8.7	46	13.5
Total		494	100.0	341	100.0

Figure 3.4.2: Regional distribution of leukaemia (ASR*) among Saudi nationals, 2020.





Figure 3.4.3: Comparison of ASR* for leukaemia among Saudis with ASR in selected countries**



**Source for this information is summarized on page 58.

Non-Hodgkin Lymphoma (C82-C85; C96).

Non-Hodgkin Lymphoma (NHL) was ranked third among Saudi males and sixth among Saudi females. There were 756 cases accounting for 5.4% of all cancers diagnosed among Saudi nationals in 2020. NHL affected 420 (55.6%) males, and 336 (44.4%) females, with a male to female ratio of 125 to 100. The ASR was 4.6/100,000 for males and 3.9/100,000 for females. The five regions with the highest ASR in males were Eastern region at 6.1/100,000, followed by Riyadh at 6/100,000, then Najran at 5.7/100,000, then the Tabuk at 5.5/100,000, and Makkah at 4.5/100,000. In females, regions with the highest ASR were Riyadh Region at 6.3/100,000, followed by Tabuk at 5.1/100,000, then Najran at 4.9/100,000, then Eastern region at 4.5/100,000, and Makkah at 3.7/100,000 (Figure 3.5.3). The median age at diagnosis was 50 years in males (ranging between 3 and 95) and 53 years in females (ranging between 2 and 98).

Figure 3.5.1: Age-Specific Incidence Rate (AIR) for NHL among Saudi nationals, 2020.




Table 3.5.1: Morphological distribution of NHL among Saudi nationals, 2020.

Code	Morphology	Male	%	Female	%
96803	Malignant lymphoma, large B-cell, diffuse, NOS	257	61.2	202	60.1
95903	Malignant lymphoma, NOS	34	8.1	23	6.8
95913	Malignant lymphoma, non-Hodgkin, NOS	23	5.5	17	5.1
97023	Mature T-cell lymphoma, NOS	18	4.3	8	2.4
96903	Follicular lymphoma, NOS	14	3.3	10	3.0
96873	Burkitt lymphoma, NOS	11	2.6	2	0.6
96913	Follicular lymphoma, grade 2	10	2.4	12	3.6
97003	Mycosis fungoides	10	2.4	18	5.4
96993	Marginal zone B-cell lymphoma, NOS	7	1.7	16	4.8
96893	Splenic marginal zone B-cell lymphoma	6	1.4	3	0.9
	Others	30	7.1	25	7.4
Total		420	100.0	336	100.0

Figure 3.5.3: Regional distribution of NHL (ASR*) among Saudi nationals, 2020.





Figure 3.5.4: Comparison of ASR* for NHL among Saudis with selected countries*



**Source for this information is summarized on page 58.

Hodgkin's Lymphoma (C81)

Hodgkin's lymphoma was ranked sixth among Saudi males and seventh among Saudi females. There were 581 cases of Hodgkin's lymphoma accounting for 4.1% of all cancer cases diagnosed among Saudi nationals in 2020. Hodgkin's lymphoma affected 347 (59.7 %) males and 234 (40.3 %) females, with a ratio of male to female of 148 to 100. The ASR was 3.3/100,000 for males and 2.2/100,000 for females. The five regions with the highest ASR in males were Najarn at 7.4/100,000, followed by Tabuk at 6.5/100,000, and Jouf at 4.6/100,000, then Eastern region at 4.2/100,000 and Northern region at 4/100,000. In females, regions with the highest ASR were Tabuk at 3.5/100,000, followed by Eastern region at 3.3/100,000, then Riyadh region at 2.6/100,000, then Najran at 2.5/100,000 and Makkah region at 2.3/100,000 (Figure 3.6.3). The median age at diagnosis was 28 years (ranging between 0 and 91) in males and 26.5 years (ranging between 0 and 83) in females.

Figure 3.6.1: Age-Specific Incidence Rate (AIR) for Hodgkin's lymphoma among Saudi nationals, 2020.




Table 3.6.1: Morphological distribution of Hodgkin's lymphoma among Saudi nationals, 2020.

Code	Morphology	Male	%	Female	%
96503	Hodgkin lymphoma, NOS	195	56.2	120	51.3
96633	Hodgkin lymphoma, nodular sclerosis, NOS	81	23.3	76	32.5
96593	Hodgkin lymphoma, nodular lymphocyte predominance	31	8.9	12	5.1
96523	Hodgkin lymphoma, mixed cellularity, NOS	30	8.6	19	8.1
96513	Hodgkin lymphoma, lymphocyte-rich	9	2.6	4	1.7
96533	Hodgkin lymphoma, lymphocyte depletion, NOS	1	0.3	-	0.0
96643	Hodgkin lymphoma, nodular sclerosis, cellular phase	-	0.0	2	0.9
96653	Hodgkin lymphoma, nodular sclerosis, grade 1	-	0.0	1	0.4
Total		347	100.0	234	100.0

Figure 3.6.3: Regional distribution of Hodgkin’s lymphoma (ASR*) among Saudi nationals, 2020.





Figure 3.6.4: Comparison of ASR* for Hodgkin’s lymphoma among Saudis with ASR in selected countries .**



**Source for this information is summarized on page 58.

Corpus Uteri Cancer (C54).

Corpus uteri cancer was ranked fourth among Saudi females with 494 cases accounting for 6.3% of all cancer cases diagnosed among Saudi females and 3.5% of all cancer cases diagnosed among Saudi nationals in 2020. The ASR was 6.9/100,000 for the Saudi female population. The five regions with the highest ASR were Riyadh at 13/100,000, followed by Eastern region at 11.6/100,000, then Baha at 6.7/100,000, and Qassim at 6.3/100,000 and Jouf at 6/100,000 (Figure 3.7.3). The median age at diagnosis was 62 years (ranging between 23 and 100).

Figure 3.7.1: Age-Specific Incidence Rate (AIR) for corpus uteri cancer among Saudi females, 2020.




Table 3.7.1: Morphological distribution of corpus uteri cancer among Saudi females, 2020.

Code	Morphology	Female	%
83803	Endometrioid adenocarcinoma, NOS	317	64.2
81403	Adenocarcinoma, NOS	57	11.5
80003	Neoplasm, malignant	25	5.1
89803	Carcinosarcoma, NOS	24	4.9
80103	Carcinoma, NOS	20	4.0
89503	Mullerian mixed tumor	9	1.8
83103	Clear cell adenocarcinoma, NOS	7	1.4
85703	Adenocarcinoma with squamous metaplasia	6	1.2
89303	Endometrial stromal sarcoma, NOS	5	1.0
88903	Leiomyosarcoma, NOS	4	0.8
	Others	20	4.0
Total		494	100.0

Figure 3.7.2: Stage distribution of corpus uteri cancer among Saudi females, 2020.




Figure 3.7.3: Regional distribution of corpus uteri cancer (ASR*) among Saudi females, 2020.





Figure 3.7.4: Comparison of ASR* for corpus uteri cancer among Saudi females with ASR in selected countries**



**Source for this information is summarized on page 58.

Brain, Central nervous system (C70-C72).

Brain, CNS was ranked ninth among Saudi males and Saudi females. There were 488 cases of Brain, CNS accounting for 3.5% of all cancer cases diagnosed among Saudi nationals in 2020. Brain, CNS affected 283 (58.0%) males and 205 (42.0%) females, with a ratio of male to female of 138 to 100. The ASR was 3/100,000 for males and 2.2/100,000 for females. The five regions with the highest ASR in males were Riyadh at 4.4/100,000, and Najran at 4.2/100,000, followed by Qassim at 3.7/100,000, then Madinah at 3.6/100,000, and Eastern region at 3.3/100,000. In females, regions with the highest ASR were Riyadh at 3.9/100,000, followed by Madinah at 3/100,000, then Northern region at 2.3/100,000, and Eastern region at 2.1/100,000, and Makkah at 2.1/100,000 (Figure 3.8.3). The median age at diagnosis was 36 years (ranging between 0 and 89) in males and 40.5 years (ranging between 0 and 92) in females.

Figure 3.8.1: Age-Specific Incidence Rate (AIR) for Brain, CNS among Saudi nationals, 2020.




Table 3.8.1: Morphological distribution of Brain, CNS among Saudi nationals, 2020.

Code	Morphology	Male	%	Female	%
94403	Glioblastoma, NOS	87	30.7	41	20.0
93803	Glioma, malignant	47	16.6	38	18.5
94003	Astrocytoma, NOS	30	10.6	12	5.9
94703	Medulloblastoma, NOS	25	8.8	11	5.4
80003	Neoplasm, malignant	22	7.8	16	7.8
95303	Meningioma, malignant	15	5.3	28	13.7
93913	Ependymoma, NOS	12	4.2	10	4.9
94513	Oligodendroglioma, anaplastic	7	2.5	3	1.5
	Others	38	13.4	46	22.4
Total		283	100.0	205	100.0

Figure 3.8.2: Stage distribution of Brain, CNS among Saudi nationals, 2020.




Figure 3.8.3: Regional distribution of Brain, CNS (ASR*) among Saudi nationals, 2020.





Figure 3.8.4: Comparison of ASR* for Brain, CNS among Saudis with ASR in selected countries**



**Source for this information is summarized on page 58.

Lung Cancer (C33 - C34)

Lung cancer was ranked fifth among Saudi males and seventeenth among Saudi females. There were 458 cases of lung cancer accounting for 3.3 % of all newly diagnosed cases among Saudis in 2020. Lung cancer affected 353 (77.1%) males and 105 (22.9%) females with a male to female ratio of 336 to 100. The ASR was 4.8/100,000 for males and 1.4/100,000 for females. The five regions with the highest ASR for males were Eastern region at 12/100,000, followed by the Northern region at 6.4/100,000, then Riyadh at 6.1/100,000, then Tabuk at 5.4/100,000, and Makkah region at 4.5/100,000. In females, regions with the highest ASR were Northern region at 4.4/100,000 and Eastern region and Riyadh both at 2.3/100,000, followed by Jouf at 1.8/100,000, then Tabuk at 1.5/100,000 (Figure 3.9.3). The median age at diagnosis was 64 years in males (ranging between 33 and 98) and 61 years in females (ranging between 22 and 93).

Figure 3.9.1: Age-Specific Incidence Rate (AIR) for lung cancer among Saudi nationals, 2020.




Table 3.9.1: Morphological distribution of lung cancer among Saudi nationals, 2020.

Code	Morphology	Male	%	Female	%
81403	Adenocarcinoma, NOS	114	32.3	48	45.7
80463	Non-small cell carcinoma	58	16.4	15	14.3
80703	Squamous cell carcinoma, NOS	57	16.1	9	8.6
80413	Small cell carcinoma, NOS	42	11.9	5	4.8
80103	Carcinoma, NOS	17	4.8	11	10.5
80003	Neoplasm, malignant	16	4.5	3	2.9
	Others	49	13.9	14	13.3
Total		353	100.0	105	100.0

Figure 3.9.2: Stage distribution of lung cancer among Saudi nationals, 2020.




Figure 3.9.3: Regional distribution of lung cancer (ASR*) among Saudi nationals, 2020.





Figure 3.9.4: Comparison of ASR* for lung cancer among Saudis with ASR in selected Countries**



**Source for this information is summarized on page 58.

Liver Cancer (C22).

Liver cancer was ranked seventh among Saudi males and tenth among Saudi females. There were 450 Liver cancer cases accounting for 3.2% of all cancer cases diagnosed among Saudi nationals in 2020. Liver cancer affected 291 (64.7%) males and 159 (35.3%) females with a male to female ratio of 183 to 100. The ASR was 4/100,000 for males and 2.2/100,000 for females. The five regions with the highest ASR for males were Najran at 7.9/100,000, followed by Eastern region at 6.6/100,000, followed by Riyadh at 5.1/100,000 and Madinah regions at 5/100,000, followed by Makkah and Jouf both at 3.7/100,000. In females, regions with the highest ASR were Riyadh at 3.4/100,000, followed by Jouf at 3/100,000, then Najran at 2.9/100,000, then Tabuk at 2.8/100,000 and Northern region at 2.5/100,000 (Figure 3.10.3). The median age at diagnosis was 65 years in males (ranging between 21 and 97) and 65 years in females (ranging between 29 and 93).

Figure 3.10.1: Age-Specific Incidence Rate (AIR) for liver cancer among Saudi nationals, 2020.




Table 3.10.1: Morphological distribution of liver cancer among Saudi nationals, 2020.

Code	Morphology	Male	%	Female	%
81703	Hepatocellular carcinoma, NOS	201	69.1	89	56.0
81603	Cholangiocarcinoma	30	10.3	22	13.8
81403	Adenocarcinoma, NOS	27	9.3	26	16.4
82463	Neuroendocrine carcinoma, NOS	9	3.1	2	1.3
80003	Neoplasm, malignant	5	1.7	3	1.9
80103	Carcinoma, NOS	3	1.0	3	1.9
	Others	16	5.5	14	8.8
Total		291	100.0	159	100.0

Figure 3.10.2: Stage distribution of liver cancer among Saudi nationals, 2020.




Figure 3.10.3: Regional distribution of liver cancer (ASR*) among Saudi nationals, 2020.





Figure 3.10.4: Comparison of ASR* for liver cancer among Saudis with ASR in selected countries**



**Source for this information is summarized on page 58.

REFERENCES

1. GLOBOCAN 2022, Cancer Incidence and Mortality Worldwide, IARC, Lyon: International Agency for Research on Cancer. Available at: <https://gco.iarc.fr/today/home>
2. Cancer Incidence among Nationals of the GCC States, 2017
3. General Authority for statistics, Saudi Arabia



PART IV

CANCER INCIDENCE AMONG NON-SAUDIS 2020



Cancer Incidence Among Non-Saudi Population, 2020.

Between January and December 2020, a total of 3274 cancer cases were reported among the Non-Saudi population, 33 cases were excluded from analysis due to In Situ and mismatch between ICD-O-3 and ICD-10 codes. Therefore, the total Number of Cases analyzed was 3241 Out of this 1669 (51.5 %) were males and 1572 (48.5 %) were females.

Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly; the pattern of cancer had some significant differences. Those who were under 15 represented 15.2% of the population, those aged 60 and above represented 3.8%, and the 15 to 59 age group represented 81% of the non-Saudi population.

In 2020, approximately 4.4 % of all cancers occurred before the age of 15 years, 21.3% occurred between the ages of 15 to 39 years, 55.0% were between the ages of 40 to 64 years, and 19.2 % occurred after the age of 64 years. The median age at diagnosis was 51 years in males (ranging between 0 and 96) and 46 years in females (ranging between 0 and 100).

Table 4.1: Ten most common cancers among non-Saudi population, 2020.

Sites	3241	%
Breast	658	20.3
Colorectal	355	11.0
Leukaemia	232	7.2
Thyroid	171	5.3
NHL	143	4.4
Lung	137	4.2
Brain, CNS	111	3.4
Bladder	96	3.0
Other Skin	93	2.9
Prostate	89	2.7
Other Sites	1156	35.7


Table 4.2: Distribution of cancer cases among non-Saudi by nationality and gender, 2020.

Nationality	Male	%	Female	%	Total	%
Yemen	331	19.8	326	20.7	657	20.3
Egypt	232	13.9	177	11.3	409	12.6
Syrian Arab Republic	161	9.6	183	11.6	344	10.6
Philippines	67	4.0	183	11.6	250	7.7
Sudan	134	8.0	109	6.9	243	7.5
India	129	7.7	58	3.7	187	5.8
Pakistan	103	6.2	67	4.3	170	5.2
Jordan	59	3.5	59	3.8	118	3.6
Bangladesh	77	4.6	28	1.8	105	3.2
Palestine	51	3.1	41	2.6	92	2.8
Non-Saudi, NOS	41	2.5	23	1.5	64	2.0
Myanmar (formerlyBur	36	2.2	18	1.1	54	1.7
Lebanon	28	1.7	12	0.8	40	1.2
Eritrea	14	0.8	23	1.5	37	1.1
United States of Ame	23	1.4	13	0.8	36	1.1
Ethiopia	8	0.5	27	1.7	35	1.1
Indonesia	6	0.4	27	1.7	33	1.0
Afghanistan	12	0.7	14	0.9	26	0.8
Kuwait	5	0.3	20	1.3	25	0.8
Somalia	15	0.9	9	0.6	24	0.7
Sri Lanka	11	0.7	8	0.5	19	0.6
Bahrain	6	0.4	12	0.8	18	0.6
United Kingdom	14	0.8	4	0.3	18	0.6
Morocco	3	0.2	14	0.9	17	0.5
Nigeria	6	0.4	11	0.7	17	0.5
Other Nationalities	97	5.8	106	6.7	203	6.3
Total	1669	100.0	1572	100.0	3241	100.0

Table 4.3: Most common cancers among the non-Saudi population by gender, 2020.

Male	1669	%	Female	1572	%
Colorectal	256	15.3	Breast	646	41.1
Leukaemia	155	9.3	Thyroid	116	7.4
Lung	107	6.4	Colorectal	99	6.3
NHL	103	6.2	Leukaemia	77	4.9
Prostate	89	5.3	Corpus Uteri	64	4.1
Bladder	83	5.0	Ovary	45	2.9
Brain, CNS	72	4.3	Non-Hodgkin lymphoma	40	2.5
Other Skin	69	4.1	Brain, Nervous system	39	2.5
Stomach	60	3.6	Cervix Uteri	36	2.3
Thyroid	55	3.3	Hodgkin's lymphoma	34	2.2
Other Sites	620	37.1	Other Sites	376	23.9

Figure 4.1: Age-Specific Incidence Rate (AIR) for all cancers among Non-Saudi population, 2020.





PART V

INCIDENCE TABLES



Table 5.1.1: Number Of Cases Among Saudi Males by Primary Site And Age Groups, 2020

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	14	0	0	0	0	0	0	0	1	0	1	1	0	2	2	1	1	5	%0.20
C01-C02	Tongue	62	0	0	0	0	1	0	1	4	4	4	7	7	8	12	6	4	4	%1.00
C03-C06	Mouth	68	0	0	0	0	0	1	0	0	4	5	1	6	5	11	12	6	17	%1.10
C07-C08	Salivary glands	23	0	0	0	0	1	1	3	3	2	4	2	2	0	0	3	0	2	%0.40
C09	Tonsil	4	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0	0	0	%0.10
C10	Other Oropharynx	5	0	0	0	0	0	1	1	0	0	0	1	0	1	0	0	1	0	%0.10
C11	Nasopharynx	139	2	0	0	3	6	2	6	4	12	15	15	22	22	13	9	4	4	%2.20
C12-C13	Hypopharynx	6	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	2	2	%0.10
C14	Pharynx unspec.	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	%0.00
C15	Oesophagus	76	1	0	0	0	0	1	2	0	1	4	4	6	8	9	12	9	19	%1.20
C16	Stomach	164	0	0	0	0	1	2	0	4	4	5	11	19	29	19	23	15	32	%2.60
C17	Small intestine	50	0	0	0	0	0	0	0	1	5	3	5	6	9	6	3	2	10	%0.80
C18	Colon	597	7	0	0	0	1	2	7	17	30	37	34	65	103	82	57	64	91	%9.60
C19-C20	Rectum	369	3	0	0	0	0	2	3	4	24	19	26	42	51	67	39	39	50	%5.90
C21	Anus	26	0	0	0	0	0	0	2	0	0	1	2	1	4	5	4	5	2	%0.40
C22	Liver	291	0	3	1	2	2	2	1	2	2	6	12	17	38	44	38	41	80	%4.70
C23-C24	Gallbladder etc.	77	0	0	0	0	0	0	0	0	3	1	7	10	11	17	7	10	11	%1.20
C25	Pancreas	226	1	0	0	0	0	1	0	2	6	9	14	31	36	39	37	19	31	%3.60
C30-C31	Nose, sinuses etc.	33	0	1	0	0	1	1	1	0	5	2	4	4	3	2	5	1	3	%0.50
C32	Larynx	72	1	0	0	0	0	0	0	1	0	2	1	8	15	15	6	7	16	%1.20
C33-C34	Trachea,Bronchus,Lung	353	4	0	0	0	0	0	0	1	3	10	15	35	50	68	50	37	80	%5.70
C37-C38	Other Thoracic organs	35	0	2	0	0	0	3	2	4	3	3	1	2	4	2	1	4	4	%0.60
C40-C41	Bone	132	0	6	4	23	24	17	10	9	4	5	7	3	5	3	2	4	6	%2.10
C43	Melanoma of Skin	13	0	0	0	0	0	0	0	0	2	1	1	0	1	4	0	1	3	%0.20
C44	Other Skin	122	4	1	0	2	1	1	3	6	4	7	5	10	5	9	16	14	34	%2.00
C45	Mesothelioma	10	0	0	0	0	0	0	0	1	0	0	1	0	0	2	1	0	5	%0.20
C46	Kaposi sarcoma	22	0	0	0	1	1	0	0	0	3	0	0	1	1	3	1	2	9	%0.40
C47;C49	Connective,Soft tissue	99	0	7	3	3	9	6	5	6	6	11	7	6	8	11	5	3	3	%1.60
C50	Breast	40	0	0	0	0	0	2	1	2	4	1	3	6	8	3	3	3	4	%0.60
C60	Penis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	%0.00
C61	Prostate	366	4	0	0	0	0	1	0	0	0	1	5	14	37	53	58	64	129	%5.90
C62	Testis	147	0	2	0	0	9	24	32	34	19	9	4	6	6	1	0	0	1	%2.40
C63	Other male genital	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	%0.00
C64	Kidney	228	1	14	2	0	0	4	4	6	15	15	20	27	24	39	19	13	25	%3.70
C65	Renal Pelvis	9	0	0	0	0	0	0	0	0	2	0	1	2	1	2	1	0	0	%0.10
C66	Ureter	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	2	%0.10
C67	Bladder	291	5	1	0	0	0	1	2	2	7	8	16	23	39	51	34	27	75	%4.70
C68	Other Urinary organs	13	0	0	0	0	0	0	0	0	0	0	0	0	3	6	0	2	2	%0.20
C69	Eye	20	0	10	1	0	0	0	0	0	0	1	0	3	1	0	1	0	3	%0.30
C70-C72	Brain, Nervous system	283	0	32	31	21	16	10	17	11	13	12	16	30	20	14	13	9	18	%4.60
C73	Thyroid	228	1	0	2	1	8	5	23	15	27	23	26	19	22	18	12	10	16	%3.70
C74	Adrenal gland	16	0	10	2	0	0	0	0	3	1	0	0	0	0	0	0	0	0	%0.30
C75	Other Endocrine	4	0	0	1	0	0	0	0	0	0	0	1	1	0	1	0	0	0	%0.10
C81	Hodgkin disease	347	3	20	28	30	30	32	42	30	25	9	19	26	20	8	11	5	9	%5.60
C82-C85;C96	Non-Hodgkin lymphoma	420	4	2	15	12	15	21	17	27	33	30	34	39	47	30	32	22	40	%6.80
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00
C90	Multiple Myeloma	94	1	0	0	0	0	1	0	3	3	6	8	17	11	9	16	2	17	%1.50
C91	Lymphoid Leukaemia	150	0	28	10	7	18	2	6	1	10	6	9	6	6	7	11	8	15	%2.40
C92-C94	Myeloid Leukaemia	210	0	14	8	4	12	11	11	18	14	12	16	14	14	21	16	11	14	%3.40
C95	Leukaemia unspec.	134	0	29	25	16	6	4	3	7	9	2	5	9	2	8	3	3	3	%2.20
Other	Other & unspecified	112	1	8	0	3	1	2	4	7	4	6	9	8	10	15	8	14	12	%1.80
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	6209	43	190	133	128	163	163	210	236	313	296	376	554	693	733	579	488	911	%100.00
Not C44	All sites but C44	6087	39	189	133	126	162	162	207	230	309	289	371	544	688	724	563	474	877	%98.00

Table 5.1.2: Number Of Cases Among Saudi Females by Primary Site And Age Groups, 2020

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	8	1	0	0	0	0	0	0	0	0	0	2	1	0	0	1	1	2	%0.10
C01-C02	Tongue	58	2	0	0	0	0	0	2	1	1	2	8	8	6	14	4	3	7	%0.70
C03-C06	Mouth	40	0	0	1	0	0	1	0	1	0	2	3	5	3	7	4	4	9	%0.50
C07-C08	Salivary glands	12	0	0	0	0	1	0	1	1	2	1	0	1	0	2	2	1	0	%0.20
C09	Tonsil	3	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0	0	0	%0.00
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00
C11	Nasopharynx	57	0	0	0	0	8	1	2	4	5	6	7	5	7	5	4	1	2	%0.70
C12-C13	Hypopharynx	6	0	0	0	0	0	0	0	1	0	0	1	2	1	0	1	0	0	%0.10
C14	Pharynx unspec.	5	0	0	0	0	0	0	0	0	1	0	0	0	1	3	0	0	0	%0.10
C15	Oesophagus	32	0	0	0	0	0	0	1	1	1	2	1	2	0	6	4	2	12	%0.40
C16	Stomach	125	0	0	1	0	0	2	6	4	9	12	4	16	18	11	9	11	22	%1.60
C17	Small intestine	27	2	0	0	0	0	0	0	1	1	0	1	3	5	5	3	1	5	%0.30
C18	Colon	519	7	0	1	0	1	3	5	15	30	40	49	60	94	64	47	41	62	%6.60
C19-C20	Rectum	244	1	0	0	0	0	1	2	8	12	18	21	28	35	34	24	17	43	%3.10
C21	Anus	12	0	0	0	0	0	0	0	0	0	1	2	2	1	1	1	1	3	%0.20
C22	Liver	159	0	4	0	0	1	0	1	2	4	6	7	10	18	22	31	23	30	%2.00
C23-C24	Gallbladder etc.	89	0	0	0	0	0	0	0	1	2	3	5	11	19	13	12	8	15	%1.10
C25	Pancreas	131	1	0	0	0	0	1	1	0	1	8	7	15	17	27	21	9	23	%1.70
C30-C31	Nose, sinuses etc.	18	0	1	0	1	0	1	1	0	3	1	0	0	5	2	2	1	0	%0.20
C32	Larynx	7	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	2	%0.10
C33-C34	Trachea,Bronchus,Lung	105	1	0	0	0	0	1	2	5	5	7	6	12	9	19	13	10	15	%1.30
C37-C38	Other Thoracic organs	23	0	3	1	0	0	1	2	2	1	3	3	1	2	1	0	0	3	%0.30
C40-C41	Bone	91	0	3	6	10	11	13	13	1	6	2	5	8	3	4	1	3	2	%1.20
C43	Melanoma of Skin	8	0	0	0	0	0	0	1	0	1	0	0	1	0	3	1	0	1	%0.10
C44	Other Skin	88	0	0	1	0	0	2	0	2	4	8	0	5	7	7	7	11	34	%1.10
C45	Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1	%0.00
C46	Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0	0	2	1	1	1	0	0	1	%0.10
C47;C49	Connective,Soft tissue	86	0	7	1	3	7	4	2	9	7	9	6	10	5	8	4	3	1	%1.10
C50	Breast	2459	15	0	0	0	0	13	49	120	241	310	389	368	350	264	144	85	111	%31.40
C51	Vulva	16	0	0	0	1	0	0	1	2	2	1	1	2	3	1	0	0	2	%0.20
C52	Vagina	5	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2	0	1	%0.10
C53	Cervix Uteri	135	0	0	0	0	0	2	1	5	16	17	14	20	18	15	11	6	10	%1.70
C54	Corpus Uteri	494	0	0	0	0	0	3	3	7	13	16	30	46	82	96	89	56	53	%6.30
C55	Uterus unspec.	118	0	0	0	0	0	0	3	3	4	3	6	21	19	16	17	18	8	%1.50
C56	Ovary	234	0	0	3	8	9	8	10	8	16	18	25	22	32	29	17	14	15	%3.00
C57	Other Female Genital	34	0	0	0	0	0	1	0	1	1	2	2	3	4	5	6	3	6	%0.40
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00
C64	Kidney	150	1	16	1	0	1	3	1	3	5	9	17	25	23	15	10	10	10	%1.90
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00
C67	Bladder	57	0	0	1	1	0	1	3	0	2	2	3	3	5	8	7	8	13	%0.70
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	%0.00
C69	Eye	18	0	10	2	0	0	0	0	0	0	0	1	3	0	1	0	1	0	%0.20
C70-C72	Brain, Nervous system	205	1	19	12	13	13	5	4	26	8	12	15	27	20	15	7	7	1	%2.60
C73	Thyroid	816	3	0	0	5	23	52	86	94	107	101	104	83	61	39	25	14	19	%10.40
C74	Adrenal gland	21	0	8	3	0	0	0	0	1	1	2	2	0	0	1	2	1	0	%0.30
C75	Other Endocrine	5	0	0	1	0	0	1	0	0	0	1	1	1	0	0	0	0	0	%0.10
C81	Hodgkin disease	234	2	12	11	24	30	33	27	26	17	13	8	12	5	6	5	1	2	%3.00
C82-C85;C96	Non-Hodgkin lymphoma	336	4	2	3	5	7	8	17	21	32	12	31	39	40	33	25	21	36	%4.30
C88	Immunoproliferative dis.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	%0.00
C90	Multiple Myeloma	70	0	0	0	0	1	0	1	2	0	4	8	9	11	14	8	7	5	%0.90
C91	Lymphoid Leukaemia	84	0	13	7	9	12	5	1	5	0	3	5	9	4	3	3	3	2	%1.10
C92-C94	Myeloid Leukaemia	156	0	10	6	3	15	6	10	13	10	11	11	13	16	13	5	5	9	%2.00
C95	Leukaemia unspec.	101	0	24	15	8	8	5	4	0	3	4	6	2	7	4	6	2	3	%1.30
Other	Other & unspecified	129	0	9	2	4	3	4	0	6	6	7	10	13	12	18	15	4	16	%1.60
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	7841	41	141	79	95	151	181	263	403	580	680	830	930	971	860	601	418	617	%100.00
Not C44	All sites but C44	7753	41	141	78	95	151	179	263	401	576	672	830	925	964	853	594	407	583	%98.90

Table 5.1.3: Age-Specific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site and Age groups, 2020

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World	
C00	Lip	14	0	0	0	0	0	0	0	0.1	0	0.1	0.2	0	0.6	0.8	0.6	0.9	3	0.1	0.2	
C01-C02	Tongue	62	0	0	0	0	0.1	0	0.1	0.4	0.5	0.6	1.2	1.5	2.2	4.6	3.8	3.5	2.4	0.6	0.8	
C03-C06	Mouth	68	0	0	0	0	0	0.1	0	0	0.5	0.7	0.2	1.3	1.4	4.2	7.6	5.2	10.2	0.6	0.9	
C07-C08	Salivary glands	23	0	0	0	0	0.1	0.1	0.3	0.3	0.2	0.6	0.3	0.4	0	0	1.9	0	1.2	0.2	0.2	
C09	Tonsil	4	0	0	0	0	0	0	0	0	0	0	0	0.2	0.6	0.4	0	0	0	0	0	
C10	Other Oropharynx	5	0	0	0	0	0	0.1	0.1	0	0	0	0.2	0	0.3	0	0	0.9	0	0	0.1	
C11	Nasopharynx	139	2	0	0	0.3	0.6	0.2	0.6	0.4	1.5	2.2	2.6	4.8	6.1	5	5.7	3.5	2.4	1.3	1.5	
C12-C13	Hypopharynx	6	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0.6	1.7	1.2	0.1	0.1	
C14	Pharynx unspec.	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.2	0	0	
C15	Oesophagus	76	1	0	0	0	0	0.1	0.2	0	0.1	0.6	0.7	1.3	2.2	3.5	7.6	7.8	11.4	0.7	1	
C16	Stomach	164	0	0	0	0	0.1	0.2	0	0.4	0.5	0.7	1.9	4.1	8.1	7.3	14.5	12.9	19.2	1.5	2.1	
C17	Small intestine	50	0	0	0	0	0	0	0	0.1	0.6	0.4	0.9	1.3	2.5	2.3	1.9	1.7	6	0.5	0.6	
C18	Colon	597	7	0	0	0	0.1	0.2	0.7	1.8	3.7	5.4	5.9	14.1	28.6	31.4	35.9	55.2	54.5	5.5	7.6	
C19-C20	Rectum	369	3	0	0	0	0	0.2	0.3	0.4	2.9	2.8	4.5	9.1	14.2	25.7	24.6	33.7	29.9	3.4	4.8	
C21	Anus	26	0	0	0	0	0	0	0.2	0	0	0.1	0.3	0.2	1.1	1.9	2.5	4.3	1.2	0.2	0.4	
C22	Liver	291	0	0.3	0.1	0.2	0.2	0.2	0.1	0.2	0.2	0.9	2.1	3.7	10.6	16.9	23.9	35.4	47.9	2.7	4	
C23-C24	Gallbladder etc.	77	0	0	0	0	0	0	0	0	0.4	0.1	1.2	2.2	3.1	6.5	4.4	8.6	6.6	0.7	1	
C25	Pancreas	226	1	0	0	0	0	0.1	0	0.2	0.7	1.3	2.4	6.7	10	15	23.3	16.4	18.6	2.1	3	
C30-C31	Nose, sinuses etc.	33	0	0.1	0	0	0.1	0.1	0.1	0	0.6	0.3	0.7	0.9	0.8	0.8	3.2	0.9	1.8	0.3	0.4	
C32	Larynx	72	1	0	0	0	0	0	0	0.1	0	0.3	0.2	1.7	4.2	5.8	3.8	6	9.6	0.7	1	
C33-C34	Trachea,Bronchus,Lung	353	4	0	0	0	0	0	0	0.1	0.4	1.5	2.6	7.6	13.9	26.1	31.5	31.9	47.9	3.2	4.8	
C37-C38	Other Thoracic organs	35	0	0.2	0	0	0	0.3	0.2	0.4	0.4	0.4	0.2	0.4	1.1	0.8	0.6	3.5	2.4	0.3	0.4	
C40-C41	Bone	132	0	0.5	0.4	2.3	2.5	1.5	1	1	0.5	0.7	1.2	0.7	1.4	1.2	1.3	3.5	3.6	1.2	1.2	
C43	Melanoma of Skin	13	0	0	0	0	0	0	0	0	0.2	0.1	0.2	0	0.3	1.5	0	0.9	1.8	0.1	0.2	
C44	Other Skin	122	4	0.1	0	0.2	0.1	0.1	0.3	0.6	0.5	1	0.9	2.2	1.4	3.5	10.1	12.1	20.4	1.1	1.6	
C45	Mesothelioma	10	0	0	0	0	0	0	0	0.1	0	0	0.2	0	0	0.8	0.6	0	3	0.1	0.1	
C46	Kaposi sarcoma	22	0	0	0	0.1	0.1	0	0	0	0.4	0	0	0.2	0.3	1.2	0.6	1.7	5.4	0.2	0.3	
C47;C49	Connective,Soft tissue	99	0	0.6	0.3	0.3	0.9	0.5	0.5	0.6	0.7	1.6	1.2	1.3	2.2	4.2	3.2	2.6	1.8	0.9	1	
C50	Breast	40	0	0	0	0	0	0.2	0.1	0.2	0.5	0.1	0.5	1.3	2.2	1.2	1.9	2.6	2.4	0.4	0.5	
C60	Penis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	0	0	
2	Prostate	366	4	0	0	0	0	0.1	0	0	0	0.1	0.9	3	10.3	20.3	36.5	55.2	77.2	3.3	5.2	
C62	Testis	147	0	0.2	0	0	0.9	2.2	3.1	3.7	2.3	1.3	0.7	1.3	1.7	0.4	0	0	0.6	1.3	1.2	
C63	Other male genital	1	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	
C64	Kidney	228	1	1.2	0.2	0	0	0.4	0.4	0.6	1.8	2.2	3.5	5.9	6.7	15	12	11.2	15	2.1	2.8	
C65	Renal Pelvis	9	0	0	0	0	0	0	0	0	0.2	0	0.2	0.4	0.3	0.8	0.6	0	0	0.1	0.1	
C66	Ureter	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	1.3	0	1.2	0	0.1	
C67	Bladder	291	5	0.1	0	0	0	0.1	0.2	0.2	0.9	1.2	2.8	5	10.8	19.6	21.4	23.3	44.9	2.7	3.9	
C68	Other Urinary organs	13	0	0	0	0	0	0	0	0	0	0	0	0	0.8	2.3	0	1.7	1.2	0.1	0.2	
C69	Eye	20	0	0.9	0.1	0	0	0	0	0	0	0.1	0	0.7	0.3	0	0.6	0	1.8	0.2	0.2	
C70-C72	Brain, Nervous system	283	0	2.8	2.7	2.1	1.7	0.9	1.7	1.2	1.6	1.7	2.8	6.5	5.6	5.4	8.2	7.8	10.8	2.6	3	
C73	Thyroid	228	1	0	0.2	0.1	0.8	0.5	2.2	1.6	3.3	3.3	4.5	4.1	6.1	6.9	7.6	8.6	9.6	2.1	2.4	
C74	Adrenal gland	16	0	0.9	0.2	0	0	0	0	0.3	0.1	0	0	0	0	0	0	0	0	0.1	0.1	
C75	Other Endocrine	4	0	0	0.1	0	0	0	0	0	0	0	0.2	0.2	0	0.4	0	0	0	0	0	
C81	Hodgkin disease	347	3	1.7	2.5	3	3.1	2.9	4.1	3.2	3.1	1.3	3.3	5.6	5.6	3.1	6.9	4.3	5.4	3.2	3.3	
C82-C85;C96	Non-Hodgkin lymphoma	420	4	0.2	1.3	1.2	1.6	1.9	1.7	2.9	4.1	4.4	5.9	8.5	13	11.5	20.2	19	23.9	3.8	4.6	
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C90	Multiple Myeloma	94	1	0	0	0	0	0.1	0	0.3	0.4	0.9	1.4	3.7	3.1	3.5	10.1	1.7	10.2	0.9	1.2	
C91	Lymphoid Leukaemia	150	0	2.4	0.9	0.7	1.9	0.2	0.6	0.1	1.2	0.9	1.6	1.3	1.7	2.7	6.9	6.9	9	1.4	1.7	
C92-C94	Myeloid Leukaemia	210	0	1.2	0.7	0.4	1.3	1	1.1	1.9	1.7	1.7	2.8	3	3.9	8.1	10.1	9.5	8.4	1.9	2.3	
C95	Leukaemia unspec.	134	0	2.5	2.2	1.6	0.6	0.4	0.3	0.8	1.1	0.3	0.9	2	0.6	3.1	1.9	2.6	1.8	1.2	1.3	
Other	Other & unspecified	112	1	0.7	0	0.3	0.1	0.2	0.4	0.8	0.5	0.9	1.6	1.7	2.8	5.8	5	12.1	7.2	1	1.4	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	6209	43	16	12	13	17	15	20	25	38	43	65	120	192	281	365	421	545	56.8	74.7	
Not C44	All sites but C44	6087	39	16	12	12	17	15	20	25	38	42	64	118	191	278	355	409	525	55.7	73.1	

Table 5.1.4: Age-Specific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site and Age groups, 2020

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World	
C00	Lip	8	1	0	0	0	0	0	0	0	0	0	0.4	0.2	0	0	0.6	0.8	1.1	0.1	0.1	
C01-C02	Tongue	58	2	0	0	0	0	0	0.2	0.1	0.1	0.3	1.5	1.8	1.8	5.7	2.4	2.5	4	0.6	0.8	
C03-C06	Mouth	40	0	0	0.1	0	0	0.1	0	0.1	0	0.3	0.5	1.1	0.9	2.9	2.4	3.4	5.2	0.4	0.5	
C07-C08	Salivary glands	12	0	0	0	0	0.1	0	0.1	0.1	0.3	0.2	0	0.2	0	0.8	1.2	0.8	0	0.1	0.1	
C09	Tonsil	3	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.8	0	0	0	0	0	
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C11	Nasopharynx	57	0	0	0	0	0.9	0.1	0.2	0.4	0.6	0.9	1.3	1.1	2.1	2	2.4	0.8	1.1	0.5	0.6	
C12-C13	Hypopharynx	6	0	0	0	0	0	0	0	0.1	0	0	0.2	0.5	0.3	0	0.6	0	0	0.1	0.1	
C14	Pharynx unspec.	5	0	0	0	0	0	0	0	0	0.1	0	0	0	0.3	1.2	0	0	0	0	0.1	
C15	Oesophagus	32	0	0	0	0	0	0	0.1	0.1	0.1	0.3	0.2	0.5	0	2.5	2.4	1.7	6.9	0.3	0.4	
C16	Stomach	125	0	0	0.1	0	0	0.2	0.6	0.4	1.1	1.8	0.7	3.7	5.4	4.5	5.3	9.2	12.6	1.2	1.5	
C17	Small intestine	27	2	0	0	0	0	0	0	0.1	0.1	0	0.2	0.7	1.5	2	1.8	0.8	2.9	0.3	0.4	
C18	Colon	519	7	0	0.1	0	0.1	0.3	0.5	1.6	3.8	6	8.9	13.7	28.4	26.2	27.8	34.4	35.5	4.9	6.5	
C19-C20	Rectum	244	1	0	0	0	0	0.1	0.2	0.9	1.5	2.7	3.8	6.4	10.6	13.9	14.2	14.3	24.7	2.3	3.1	
C21	Anus	12	0	0	0	0	0	0	0	0	0	0.2	0.4	0.5	0.3	0.4	0.6	0.8	1.7	0.1	0.2	
C22	Liver	159	0	0.4	0	0	0.1	0	0.1	0.2	0.5	0.9	1.3	2.3	5.4	9	18.3	19.3	17.2	1.5	2.2	
C23-C24	Gallbladder etc.	89	0	0	0	0	0	0	0	0.1	0.3	0.5	0.9	2.5	5.7	5.3	7.1	6.7	8.6	0.8	1.2	
C25	Pancreas	131	1	0	0	0	0	0.1	0.1	0	0.1	1.2	1.3	3.4	5.1	11.1	12.4	7.6	13.2	1.2	1.8	
C30-C31	Nose, sinuses etc.	18	0	0.1	0	0.1	0	0.1	0.1	0	0.4	0.2	0	0	1.5	0.8	1.2	0.8	0	0.2	0.2	
C32	Larynx	7	0	0	0	0	0	0	0	0	0	0.2	0	0	0.3	0.4	0.6	0.8	1.1	0.1	0.1	
C33-C34	Trachea,Bronchus,Lung	105	1	0	0	0	0	0.1	0.2	0.5	0.6	1.1	1.1	2.7	2.7	7.8	7.7	8.4	8.6	1	1.4	
C37-C38	Other Thoracic organs	23	0	0.3	0.1	0	0	0.1	0.2	0.2	0.1	0.5	0.5	0.2	0.6	0.4	0	0	1.7	0.2	0.2	
C40-C41	Bone	91	0	0.3	0.5	1	1.2	1.3	1.3	0.1	0.8	0.3	0.9	1.8	0.9	1.6	0.6	2.5	1.1	0.9	0.9	
C43	Melanoma of Skin	8	0	0	0	0	0	0	0.1	0	0.1	0	0	0.2	0	1.2	0.6	0	0.6	0.1	0.1	
C44	Other Skin	88	0	0	0.1	0	0	0.2	0	0.2	0.5	1.2	0	1.1	2.1	2.9	4.1	9.2	19.5	0.8	1.1	
C45	Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0.6	0	0	
C46	Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0	0	0.4	0.2	0.3	0.4	0	0	0.6	0.1	0.1	
C47;C49	Connective,Soft tissue	86	0	0.6	0.1	0.3	0.8	0.4	0.2	1	0.9	1.4	1.1	2.3	1.5	3.3	2.4	2.5	0.6	0.8	0.9	
C50	Breast	2459	15	0	0	0	0	1.3	4.9	13.1	30.3	46.7	71	84.3	105.8	108.1	85.2	71.3	63.6	23.3	28.4	
C51	Vulva	16	0	0	0	0.1	0	0	0.1	0.2	0.3	0.2	0.2	0.5	0.9	0.4	0	0	1.1	0.2	0.2	
C52	Vagina	5	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0.4	1.2	0	0.6	0	0.1	
C53	Cervix Uteri	135	0	0	0	0	0	0.2	0.1	0.5	2	2.6	2.6	4.6	5.4	6.1	6.5	5	5.7	1.3	1.6	
C54	Corpus Uteri	494	0	0	0	0	0	0.3	0.3	0.8	1.6	2.4	5.5	10.5	24.8	39.3	52.7	47	30.4	4.7	6.9	
C55	Uterus unspec.	118	0	0	0	0	0	0	0.3	0.3	0.5	0.5	1.1	4.8	5.7	6.6	10.1	15.1	4.6	1.1	1.6	
C56	Ovary	234	0	0	0.3	0.8	1	0.8	1	0.9	2	2.7	4.6	5	9.7	11.9	10.1	11.7	8.6	2.2	2.8	
C57	Other Female Genital	34	0	0	0	0	0	0.1	0	0.1	0.1	0.3	0.4	0.7	1.2	2	3.6	2.5	3.4	0.3	0.5	
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C64	Kidney	150	1	1.4	0.1	0	0.1	0.3	0.1	0.3	0.6	1.4	3.1	5.7	7	6.1	5.9	8.4	5.7	1.4	1.8	
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C67	Bladder	57	0	0	0.1	0.1	0	0.1	0.3	0	0.3	0.3	0.5	0.7	1.5	3.3	4.1	6.7	7.5	0.5	0.7	
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	
C69	Eye	18	0	0.9	0.2	0	0	0	0	0	0	0	0.2	0.7	0	0.4	0	0.8	0	0.2	0.2	
C70-C72	Brain, Nervous system	205	1	1.7	1.1	1.3	1.4	0.5	0.4	2.8	1	1.8	2.7	6.2	6	6.1	4.1	5.9	0.6	1.9	2.2	
C73	Thyroid	816	3	0	0	0.5	2.5	5.1	8.5	10.3	13.4	15.2	19	19	18.4	16	14.8	11.7	10.9	7.7	8.1	
C74	Adrenal gland	21	0	0.7	0.3	0	0	0	0	0.1	0.1	0.3	0.4	0	0	0.4	1.2	0.8	0	0.2	0.2	
C75	Other Endocrine	5	0	0	0.1	0	0	0.1	0	0	0	0.2	0.2	0.2	0	0	0	0	0	0	0	
C81	Hodgkin disease	234	2	1.1	1	2.4	3.2	3.3	2.7	2.8	2.1	2	1.5	2.7	1.5	2.5	3	0.8	1.1	2.2	2.2	
C82-C85;C96	Non-Hodgkin lymphoma	336	4	0.2	0.3	0.5	0.8	0.8	1.7	2.3	4	1.8	5.7	8.9	12.1	13.5	14.8	17.6	20.6	3.2	3.9	
C88	Immunoproliferative dis.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	
C90	Multiple Myeloma	70	0	0	0	0	0.1	0	0.1	0.2	0	0.6	1.5	2.1	3.3	5.7	4.7	5.9	2.9	0.7	0.9	
C91	Lymphoid Leukaemia	84	0	1.2	0.6	0.9	1.3	0.5	0.1	0.5	0	0.5	0.9	2.1	1.2	1.2	1.8	2.5	1.1	0.8	0.9	
C92-C94	Myeloid Leukaemia	156	0	0.9	0.5	0.3	1.6	0.6	1	1.4	1.3	1.7	2	3	4.8	5.3	3	4.2	5.2	1.5	1.7	
C95	Leukaemia unspec.	101	0	2.1	1.4	0.8	0.9	0.5	0.4	0	0.4	0.6	1.1	0.5	2.1	1.6	3.6	1.7	1.7	1	1.1	
Other	Other & unspecified	129	0	0.8	0.2	0.4	0.3	0.4	0	0.7	0.8	1.1	1.8	3	3.6	7.4	8.9	3.4	9.2	1.2	1.6	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	7841	41	13	7	10	16	18	26	44	73	102	151	213	294	352	356	351	354	74.4	92.1	
Not C44	All sites but C44	7753	41	13	7	10	16	18	26	44	72	101	151	212	291	349	352	341	334	73.5	91	

Table 5.2.1: Number Of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardised Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site, Age Groups and Regions 2020

ICD (10th)	Site	Asir				Baha				Jazan			
		All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World
C00	Lip	0	%0.00	0	0	2	%2.40	1	1.5	1	%0.60	0.2	0.3
C01-C02	Tongue	6	%1.60	0.7	0.9	0	%0.00	0	0	6	%3.40	0.9	1.4
C03-C06	Mouth	3	%0.80	0.3	0.4	0	%0.00	0	0	11	%6.10	1.7	2.5
C07-C08	Salivary glands	1	%0.30	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C09	Tonsil	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C10	Other Oropharynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C11	Nasopharynx	8	%2.20	0.9	1	1	%1.20	0.5	0.4	5	%2.80	0.8	0.8
C12-C13	Hypopharynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C14	Pharynx unspec.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C15	Oesophagus	7	%1.90	0.8	0.9	3	%3.70	1.5	2	4	%2.20	0.6	1
C16	Stomach	12	%3.30	1.3	1.7	3	%3.70	1.5	1.6	5	%2.80	0.8	1
C17	Small intestine	3	%0.80	0.3	0.4	0	%0.00	0	0	1	%0.60	0.2	0.3
C18	Colon	45	%12.30	4.9	6.2	12	%14.60	6.2	6.4	18	%10.10	2.8	3.9
C19-C20	Rectum	27	%7.40	3	3.9	2	%2.40	1	1.2	4	%2.20	0.6	1
C21	Anus	1	%0.30	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C22	Liver	16	%4.40	1.8	2.4	5	%6.10	2.6	3.1	8	%4.50	1.2	1.6
C23-C24	Gallbladder etc.	8	%2.20	0.9	1.1	1	%1.20	0.5	0.4	2	%1.10	0.3	0.5
C25	Pancreas	11	%3.00	1.2	1.6	1	%1.20	0.5	0.4	8	%4.50	1.2	1.7
C30-C31	Nose, sinuses etc.	6	%1.60	0.7	0.8	0	%0.00	0	0	1	%0.60	0.2	0.2
C32	Larynx	4	%1.10	0.4	0.5	1	%1.20	0.5	0.6	2	%1.10	0.3	0.4
C33-C34	Trachea,Bronchus,Lung	11	%3.00	1.2	1.6	3	%3.70	1.5	1.7	5	%2.80	0.8	1.1
C37-C38	Other Thoracic organs	1	%0.30	0.1	0.2	1	%1.20	0.5	0.4	0	%0.00	0	0
C40-C41	Bone	6	%1.60	0.7	0.7	0	%0.00	0	0	2	%1.10	0.3	0.3
C43	Melanoma of Skin	2	%0.50	0.2	0.3	0	%0.00	0	0	0	%0.00	0	0
C44	Other Skin	10	%2.70	1.1	1.1	2	%2.40	1	1.4	12	%6.70	1.9	2.7
C45	Mesothelioma	0	%0.00	0	0	1	%1.20	0.5	0.8	0	%0.00	0	0
C46	Kaposi sarcoma	2	%0.50	0.2	0.3	3	%3.70	1.5	1.3	1	%0.60	0.2	0.3
C47;C49	Connective,Soft tissue	3	%0.80	0.3	0.4	2	%2.40	1	1.2	2	%1.10	0.3	0.4
C50	Breast	1	%0.30	0.1	0.2	2	%2.40	1	1	2	%1.10	0.3	0.3
C60	Penis	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C61	Prostate	22	%6.00	2.4	2.8	2	%2.40	1	1	13	%7.30	2	3.5
C62	Testis	10	%2.70	1.1	1	2	%2.40	1	0.9	4	%2.20	0.6	0.6
C63	Other male genital	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C64	Kidney	8	%2.20	0.9	1	4	%4.90	2.1	2.2	3	%1.70	0.5	0.6
C65	Renal Pelvis	1	%0.30	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C66	Ureter	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C67	Bladder	18	%4.90	2	2.4	5	%6.10	2.6	2.7	16	%8.90	2.5	4
C68	Other Urinary organs	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C69	Eye	1	%0.30	0.1	0.1	0	%0.00	0	0	1	%0.60	0.2	0.2
C70-C72	Brain, Nervous system	9	%2.50	1	0.9	2	%2.40	1	0.8	8	%4.50	1.2	1.5
C73	Thyroid	9	%2.50	1	1	2	%2.40	1	1	0	%0.00	0	0
C74	Adrenal gland	3	%0.80	0.3	0.3	0	%0.00	0	0	0	%0.00	0	0
C75	Other Endocrine	1	%0.30	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C81	Hodgkin disease	21	%5.80	2.3	2.2	7	%8.50	3.6	3.5	4	%2.20	0.6	0.6
C82-C85;C96	Non-Hodgkin lymphoma	20	%5.50	2.2	2.5	4	%4.90	2.1	2.2	18	%10.10	2.8	3.3
C88	Immunoproliferative dis.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C90	Multiple Myeloma	4	%1.10	0.4	0.6	0	%0.00	0	0	2	%1.10	0.3	0.6
C91	Lymphoid Leukaemia	9	%2.50	1	1.1	3	%3.70	1.5	1.9	2	%1.10	0.3	0.4
C92-C94	Myeloid Leukaemia	13	%3.60	1.4	1.6	4	%4.90	2.1	2.4	2	%1.10	0.3	0.3
C95	Leukaemia unspec.	12	%3.30	1.3	1.4	0	%0.00	0	0	3	%1.70	0.5	0.5
Other	Other & unspecified	10	%2.70	1.1	1.4	2	%2.40	1	0.7	3	%1.70	0.5	0.5
		----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	365	%100.00	40.1	47.2	82	%100.00	42.3	44.6	179	%100.00	27.9	38.4
Not C44	All sites but C44	355	%97.30	39	46.1	80	%97.60	41.3	43.1	167	%93.30	26	35.7

Table 5.2.2: Number Of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardised Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site, Age Groups and Regions 2020

ICD (10th)	Site	Madinah				Hail				Qassim			
		All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World
C00	Lip	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C01-C02	Tongue	1	%0.30	0.1	0.2	1	%1.00	0.4	0.5	0	%0.00	0	0
C03-C06	Mouth	1	%0.30	0.1	0.2	1	%1.00	0.4	0.6	3	%1.20	0.6	0.6
C07-C08	Salivary glands	2	%0.60	0.3	0.2	1	%1.00	0.4	0.3	1	%0.40	0.2	0.2
C09	Tonsil	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C10	Other Oropharynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C11	Nasopharynx	5	%1.50	0.7	1	0	%0.00	0	0	11	%4.30	2.1	2.4
C12-C13	Hypopharynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C14	Pharynx unspec.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C15	Oesophagus	4	%1.20	0.6	0.7	2	%2.00	0.7	1.1	5	%2.00	0.9	1.2
C16	Stomach	8	%2.40	1.1	1.5	4	%4.00	1.4	1.5	12	%4.70	2.2	3.2
C17	Small intestine	1	%0.30	0.1	0.1	1	%1.00	0.4	0.6	4	%1.60	0.7	1
C18	Colon	35	%10.40	4.8	6.6	9	%8.90	3.2	3.8	25	%9.80	4.7	6.3
C19-C20	Rectum	18	%5.30	2.5	3.4	6	%5.90	2.1	2.9	22	%8.70	4.1	5.4
C21	Anus	0	%0.00	0	0	1	%1.00	0.4	0.4	0	%0.00	0	0
C22	Liver	26	%7.70	3.6	5	4	%4.00	1.4	2.2	9	%3.50	1.7	2.2
C23-C24	Gallbladder etc.	3	%0.90	0.4	0.6	2	%2.00	0.7	1	1	%0.40	0.2	0.4
C25	Pancreas	9	%2.70	1.2	2.1	6	%5.90	2.1	2.5	17	%6.70	3.2	4.4
C30-C31	Nose, sinuses etc.	2	%0.60	0.3	0.4	0	%0.00	0	0	0	%0.00	0	0
C32	Larynx	4	%1.20	0.6	0.7	2	%2.00	0.7	1.2	4	%1.60	0.7	1.2
C33-C34	Trachea,Bronchus,Lung	14	%4.20	1.9	3.1	5	%5.00	1.8	2	5	%2.00	0.9	1.6
C37-C38	Other Thoracic organs	1	%0.30	0.1	0.1	0	%0.00	0	0	1	%0.40	0.2	0.2
C40-C41	Bone	3	%0.90	0.4	0.5	3	%3.00	1.1	1.1	5	%2.00	0.9	0.9
C43	Melanoma of Skin	2	%0.60	0.3	0.3	0	%0.00	0	0	1	%0.40	0.2	0.3
C44	Other Skin	4	%1.20	0.6	0.8	1	%1.00	0.4	0.6	2	%0.80	0.4	0.4
C45	Mesothelioma	0	%0.00	0	0	0	%0.00	0	0	1	%0.40	0.2	0.1
C46	Kaposi sarcoma	1	%0.30	0.1	0.1	0	%0.00	0	0	1	%0.40	0.2	0.2
C47,C49	Connective,Soft tissue	5	%1.50	0.7	0.7	3	%3.00	1.1	1.3	7	%2.80	1.3	1.8
C50	Breast	0	%0.00	0	0	2	%2.00	0.7	0.9	5	%2.00	0.9	1.1
C60	Penis	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C61	Prostate	22	%6.50	3	4.4	2	%2.00	0.7	0.9	10	%3.90	1.9	2.6
C62	Testis	3	%0.90	0.4	0.4	1	%1.00	0.4	0.3	9	%3.50	1.7	1.5
C63	Other male genital	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C64	Kidney	13	%3.90	1.8	2.4	3	%3.00	1.1	1.5	9	%3.50	1.7	2.4
C65	Renal Pelvis	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C66	Ureter	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C67	Bladder	19	%5.60	2.6	3.3	5	%5.00	1.8	2.6	10	%3.90	1.9	2.5
C68	Other Urinary organs	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C69	Eye	3	%0.90	0.4	0.5	0	%0.00	0	0	0	%0.00	0	0
C70-C72	Brain, Nervous system	24	%7.10	3.3	3.6	8	%7.90	2.9	2.8	18	%7.10	3.4	3.7
C73	Thyroid	10	%3.00	1.4	1.6	5	%5.00	1.8	1.9	16	%6.30	3	3.3
C74	Adrenal gland	2	%0.60	0.3	0.3	0	%0.00	0	0	0	%0.00	0	0
C75	Other Endocrine	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C81	Hodgkin disease	15	%4.50	2.1	2.1	5	%5.00	1.8	1.7	11	%4.30	2.1	2.2
C82-C85,C96	Non-Hodgkin lymphoma	30	%8.90	4.1	4.5	5	%5.00	1.8	1.8	16	%6.30	3	3.7
C88	Immunoproliferative dis.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C90	Multiple Myeloma	2	%0.60	0.3	0.3	0	%0.00	0	0	3	%1.20	0.6	0.9
C91	Lymphoid Leukaemia	11	%3.30	1.5	1.7	3	%3.00	1.1	1	0	%0.00	0	0
C92-C94	Myeloid Leukaemia	2	%0.60	0.3	0.4	3	%3.00	1.1	1.3	1	%0.40	0.2	0.4
C95	Leukaemia unspec.	23	%6.80	3.2	3.4	4	%4.00	1.4	1.6	4	%1.60	0.7	1
Other	Other & unspecified	9	%2.70	1.2	1.6	3	%3.00	1.1	1.4	5	%2.00	0.9	1.3
		----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	337	%100.00	46.4	58.9	101	%100.00	36.1	43.1	254	%100.00	47.4	60.5
Not C44	All sites but C44	333	%98.80	45.9	58	100	%99.00	35.7	42.5	252	%99.20	47	60.1

Table 5.2.3: Number Of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardised Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site, Age Groups and Regions 2020

ICD (10th)	Site	Najran				Jouf				Tabuk				Northern Region			
		All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World
C00	Lip	0	%0.00	0	0	0	%0.00	0	0	1	%0.60	0.3	0.5	0	%0.00	0	0
C01-C02	Tongue	0	%0.00	0	0	1	%1.10	0.5	0.7	0	%0.00	0	0	0	%0.00	0	0
C03-C06	Mouth	5	%4.00	2.2	4.2	0	%0.00	0	0	0	%0.00	0	0	1	%1.50	0.7	0.7
C07-C08	Salivary glands	0	%0.00	0	0	1	%1.10	0.5	1.3	0	%0.00	0	0	1	%1.50	0.7	0.6
C09	Tonsil	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C10	Other Oropharynx	0	%0.00	0	0	0	%0.00	0	0	1	%0.60	0.3	0.2	0	%0.00	0	0
C11	Nasopharynx	3	%2.40	1.3	2	3	%3.30	1.5	2.1	8	%4.40	2.1	3	3	%4.40	2	2.9
C12-C13	Hypopharynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C14	Pharynx unspec.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C15	Oesophagus	0	%0.00	0	0	1	%1.10	0.5	0.7	4	%2.20	1	1.8	0	%0.00	0	0
C16	Stomach	8	%6.40	3.5	6.9	0	%0.00	0	0	4	%2.20	1	1.6	0	%0.00	0	0
C17	Small intestine	0	%0.00	0	0	1	%1.10	0.5	0.8	0	%0.00	0	0	1	%1.50	0.7	0.6
C18	Colon	5	%4.00	2.2	3.3	8	%8.70	3.9	6.1	17	%9.40	4.4	7.8	7	%10.30	4.6	7.3
C19-C20	Rectum	3	%2.40	1.3	2	5	%5.40	2.5	4.8	7	%3.90	1.8	3.6	1	%1.50	0.7	1.2
C21	Anus	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C22	Liver	12	%9.60	5.2	7.9	4	%4.30	2	3.7	7	%3.90	1.8	3.4	0	%0.00	0	0
C23-C24	Gallbladder etc.	0	%0.00	0	0	1	%1.10	0.5	1	1	%0.60	0.3	0.5	1	%1.50	0.7	1.4
C25	Pancreas	4	%3.20	1.7	3.1	7	%7.60	3.5	4.7	3	%1.70	0.8	1	3	%4.40	2	3.9
C30-C31	Nose, sinuses etc.	0	%0.00	0	0	1	%1.10	0.5	1.3	1	%0.60	0.3	0.4	0	%0.00	0	0
C32	Larynx	0	%0.00	0	0	0	%0.00	0	0	2	%1.10	0.5	1.2	3	%4.40	2	3.4
C33-C34	Trachea,Bronchus,Lung	3	%2.40	1.3	2.5	3	%3.30	1.5	2.9	12	%6.70	3.1	5.4	5	%7.40	3.3	6.4
C37-C38	Other Thoracic organs	1	%0.80	0.4	0.6	0	%0.00	0	0	0	%0.00	0	0	1	%1.50	0.7	0.5
C40-C41	Bone	3	%2.40	1.3	2.1	5	%5.40	2.5	2.5	6	%3.30	1.5	1.6	2	%2.90	1.3	1
C43	Melanoma of Skin	1	%0.80	0.4	1.1	0	%0.00	0	0	1	%0.60	0.3	0.3	0	%0.00	0	0
C44	Other Skin	6	%4.80	2.6	4.5	4	%4.30	2	2.9	3	%1.70	0.8	1.8	0	%0.00	0	0
C45	Mesothelioma	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C46	Kaposi sarcoma	1	%0.80	0.4	0.6	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C47,C49	Connective,Soft tissue	0	%0.00	0	0	3	%3.30	1.5	1.9	5	%2.80	1.3	1.7	1	%1.50	0.7	0.7
C50	Breast	0	%0.00	0	0	0	%0.00	0	0	1	%0.60	0.3	0.2	1	%1.50	0.7	0.5
C60	Penis	0	%0.00	0	0	0	%0.00	0	0	1	%0.60	0.3	0.5	0	%0.00	0	0
C61	Prostate	3	%2.40	1.3	2.2	2	%2.20	1	1.4	4	%2.20	1	2	3	%4.40	2	3.9
C62	Testis	1	%0.80	0.4	0.4	2	%2.20	1	0.9	5	%2.80	1.3	1.1	4	%5.90	2.6	2
C63	Other male genital	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C64	Kidney	3	%2.40	1.3	2.1	3	%3.30	1.5	2.4	1	%0.60	0.3	0.4	3	%4.40	2	3.1
C65	Renal Pelvis	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C66	Ureter	0	%0.00	0	0	0	%0.00	0	0	1	%0.60	0.3	0.8	0	%0.00	0	0
C67	Bladder	2	%1.60	0.9	1.4	5	%5.40	2.5	4	14	%7.80	3.6	8.4	0	%0.00	0	0
C68	Other Urinary organs	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C69	Eye	1	%0.80	0.4	0.4	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C70-C72	Brain, Nervous system	8	%6.40	3.5	4.2	5	%5.40	2.5	2.7	3	%1.70	0.8	0.8	4	%5.90	2.6	3.2
C73	Thyroid	9	%7.20	3.9	5.6	2	%2.20	1	1.5	4	%2.20	1	1.2	5	%7.40	3.3	4.6
C74	Adrenal gland	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C75	Other Endocrine	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C81	Hodgkin disease	14	%11.20	6	7.4	7	%7.60	3.5	4.6	23	%12.80	5.9	6.5	6	%8.80	3.9	4
C82-C85,C96	Non-Hodgkin lymphoma	11	%8.80	4.7	5.7	4	%4.30	2	2	13	%7.20	3.3	5.5	2	%2.90	1.3	2
C88	Immunoproliferative dis.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C90	Multiple Myeloma	0	%0.00	0	0	0	%0.00	0	0	4	%2.20	1	1.8	2	%2.90	1.3	1.9
C91	Lymphoid Leukaemia	5	%4.00	2.2	2.5	4	%4.30	2	3.5	7	%3.90	1.8	2.9	1	%1.50	0.7	0.6
C92-C94	Myeloid Leukaemia	7	%5.60	3	3.6	5	%5.40	2.5	2.9	9	%5.00	2.3	3.4	4	%5.90	2.6	2.6
C95	Leukaemia unspec.	2	%1.60	0.9	0.8	4	%4.30	2	1.7	4	%2.20	1	1.2	2	%2.90	1.3	1.2
Other	Other & unspecified	4	%3.20	1.7	2.9	1	%1.10	0.5	0.8	3	%1.70	0.8	1	1	%1.50	0.7	0.5
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	125	%100.00	54	80.2	92	%100.00	45.4	65.8	180	%100.00	46.1	73.2	68	%100.00	44.3	60.4
Not C44	All sites but C44	119	%95.20	51.4	75.6	88	%95.70	43.4	62.9	177	%98.30	45.4	71.4	68	%100.00	44.3	60.4

Table 5.2.4: Number Of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardised Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site, Age Groups and Regions 2020

ICD (10th)	Site	Riyadh				Makkah				Eastern Province			
		All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World
C00	Lip	2	%0.10	0.1	0.1	4	%0.30	0.2	0.2	4	%0.30	0.2	0.4
C01-C02	Tongue	22	%1.20	0.9	1.3	14	%1.10	0.6	0.6	11	%0.90	0.6	1
C03-C06	Mouth	31	%1.60	1.2	2.1	5	%0.40	0.2	0.3	7	%0.60	0.4	0.7
C07-C08	Salivary glands	7	%0.40	0.3	0.3	7	%0.50	0.3	0.3	2	%0.20	0.1	0.1
C09	Tonsil	1	%0.10	0	0	1	%0.10	0	0.1	2	%0.20	0.1	0.1
C10	Other Oropharynx	2	%0.10	0.1	0.1	1	%0.10	0	0.1	1	%0.10	0.1	0
C11	Nasopharynx	43	%2.30	1.7	2.2	30	%2.30	1.2	1.4	19	%1.50	1.1	1.4
C12-C13	Hypopharynx	4	%0.20	0.2	0.3	0	%0.00	0	0	2	%0.20	0.1	0.2
C14	Pharynx unspec.	1	%0.10	0	0.1	0	%0.00	0	0	1	%0.10	0.1	0.1
C15	Oesophagus	28	%1.50	1.1	1.9	5	%0.40	0.2	0.3	13	%1.00	0.8	1.4
C16	Stomach	43	%2.30	1.7	2.7	31	%2.40	1.3	1.7	34	%2.70	2	3.4
C17	Small intestine	16	%0.80	0.6	0.9	10	%0.80	0.4	0.5	12	%1.00	0.7	1
C18	Colon	173	%9.10	6.8	10.4	158	%12.40	6.6	8.1	85	%6.80	4.9	8
C19-C20	Rectum	132	%6.90	5.2	7.9	62	%4.80	2.6	3.2	80	%6.40	4.7	8.1
C21	Anus	11	%0.60	0.4	0.7	9	%0.70	0.4	0.5	4	%0.30	0.2	0.5
C22	Liver	76	%4.00	3	5.1	67	%5.20	2.8	3.7	57	%4.60	3.3	6.6
C23-C24	Gallbladder etc.	27	%1.40	1.1	1.6	13	%1.00	0.5	0.6	17	%1.40	1	2
C25	Pancreas	69	%3.60	2.7	4.1	45	%3.50	1.9	2.3	43	%3.50	2.5	5
C30-C31	Nose, sinuses etc.	11	%0.60	0.4	0.6	6	%0.50	0.2	0.2	5	%0.40	0.3	0.5
C32	Larynx	17	%0.90	0.7	1	16	%1.30	0.7	0.8	17	%1.40	1	1.8
C33-C34	Trachea,Bronchus,Lung	95	%5.00	3.7	6.1	80	%6.30	3.3	4.5	111	%8.90	6.5	12
C37-C38	Other Thoracic organs	16	%0.80	0.6	0.7	7	%0.50	0.3	0.4	6	%0.50	0.3	0.5
C40-C41	Bone	39	%2.00	1.5	1.5	30	%2.30	1.2	1.3	28	%2.30	1.6	1.9
C43	Melanoma of Skin	1	%0.10	0	0	2	%0.20	0.1	0.1	3	%0.20	0.2	0.3
C44	Other Skin	38	%2.00	1.5	2.5	23	%1.80	1	1.2	17	%1.40	1	1.2
C45	Mesothelioma	5	%0.30	0.2	0.3	1	%0.10	0	0	2	%0.20	0.1	0.2
C46	Kaposi sarcoma	6	%0.30	0.2	0.3	3	%0.20	0.1	0.2	4	%0.30	0.2	0.5
C47,C49	Connective,Soft tissue	31	%1.60	1.2	1.4	23	%1.80	1	1	14	%1.10	0.8	1.1
C50	Breast	10	%0.50	0.4	0.6	8	%0.60	0.3	0.4	8	%0.60	0.5	0.7
C60	Penis	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C61	Prostate	133	%7.00	5.2	9.1	66	%5.20	2.7	4	84	%6.80	4.9	10.3
C62	Testis	40	%2.10	1.6	1.4	33	%2.60	1.4	1.1	33	%2.70	1.9	1.7
C63	Other male genital	0	%0.00	0	0	0	%0.00	0	0	1	%0.10	0.1	0.1
C64	Kidney	73	%3.80	2.9	4	57	%4.50	2.4	2.8	48	%3.90	2.8	4
C65	Renal Pelvis	0	%0.00	0	0	3	%0.20	0.1	0.2	5	%0.40	0.3	0.4
C66	Ureter	1	%0.10	0	0.1	3	%0.20	0.1	0.1	0	%0.00	0	0
C67	Bladder	66	%3.50	2.6	4.2	64	%5.00	2.7	3.3	67	%5.40	3.9	7.2
C68	Other Urinary organs	2	%0.10	0.1	0.1	8	%0.60	0.3	0.5	3	%0.20	0.2	0.3
C69	Eye	8	%0.40	0.3	0.3	4	%0.30	0.2	0.2	2	%0.20	0.1	0.2
C70-C72	Brain, Nervous system	93	%4.90	3.7	4.4	54	%4.20	2.2	2.6	47	%3.80	2.7	3.3
C73	Thyroid	84	%4.40	3.3	3.9	29	%2.30	1.2	1.3	52	%4.20	3	4.1
C74	Adrenal gland	9	%0.50	0.4	0.3	1	%0.10	0	0	1	%0.10	0.1	0.1
C75	Other Endocrine	3	%0.20	0.1	0.2	0	%0.00	0	0	0	%0.00	0	0
C81	Hodgkin disease	91	%4.80	3.6	3.7	78	%6.10	3.2	3.3	65	%5.20	3.8	4.2
C82-C85;C96	Non-Hodgkin lymphoma	122	%6.40	4.8	6	96	%7.50	4	4.5	78	%6.30	4.5	6.1
C88	Immunoproliferative dis.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C90	Multiple Myeloma	33	%1.70	1.3	2.1	17	%1.30	0.7	0.8	27	%2.20	1.6	2.6
C91	Lymphoid Leukaemia	50	%2.60	2	2.5	22	%1.70	0.9	1	33	%2.70	1.9	2.8
C92-C94	Myeloid Leukaemia	67	%3.50	2.6	3.3	41	%3.20	1.7	2	52	%4.20	3	4
C95	Leukaemia unspec.	47	%2.50	1.9	2.1	19	%1.50	0.8	0.9	10	%0.80	0.6	0.7
Other	Other & unspecified	24	%1.30	0.9	1.5	23	%1.80	1	1.1	24	%1.90	1.4	2
		----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	1903	%100.00	75	106.2	1279	%100.00	53.1	63.7	1241	%100.00	72.2	114.6
Not C44	All sites but C44	1865	%98.00	73.5	103.7	1256	%98.20	52.2	62.6	1224	%98.60	71.2	113.4

Table 5.3.1: Number Of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardised Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site, Age Groups and Regions 2020

ICD (10th)	Site	Asir				Baha				Jazan			
		All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World
C00	Lip	0	%0.00	0	0	0	%0.00	0	0	2	%1.00	0.3	0.4
C01-C02	Tongue	8	%1.90	0.9	1	0	%0.00	0	0	13	%6.60	2.1	2.7
C03-C06	Mouth	4	%1.00	0.4	0.5	0	%0.00	0	0	12	%6.10	1.9	2.6
C07-C08	Salivary glands	1	%0.20	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C09	Tonsil	1	%0.20	0.1	0.2	0	%0.00	0	0	0	%0.00	0	0
C10	Other Oropharynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C11	Nasopharynx	1	%0.20	0.1	0.1	0	%0.00	0	0	1	%0.50	0.2	0.2
C12-C13	Hypopharynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C14	Pharynx unspec.	2	%0.50	0.2	0.3	0	%0.00	0	0	0	%0.00	0	0
C15	Oesophagus	1	%0.20	0.1	0.1	2	%2.20	1	0.8	1	%0.50	0.2	0.2
C16	Stomach	14	%3.40	1.5	1.6	1	%1.10	0.5	0.4	4	%2.00	0.6	0.8
C17	Small intestine	0	%0.00	0	0	0	%0.00	0	0	1	%0.50	0.2	0.2
C18	Colon	22	%5.30	2.4	2.8	9	%9.90	4.3	4.4	9	%4.60	1.4	1.6
C19-C20	Rectum	13	%3.10	1.4	1.7	2	%2.20	1	0.9	1	%0.50	0.2	0.2
C21	Anus	1	%0.20	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C22	Liver	11	%2.70	1.2	1.5	3	%3.30	1.4	1.4	3	%1.50	0.5	0.6
C23-C24	Gallbladder etc.	7	%1.70	0.8	0.9	0	%0.00	0	0	2	%1.00	0.3	0.4
C25	Pancreas	4	%1.00	0.4	0.5	0	%0.00	0	0	7	%3.60	1.1	1.4
C30-C31	Nose, sinuses etc.	1	%0.20	0.1	0.1	0	%0.00	0	0	1	%0.50	0.2	0.1
C32	Larynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C33-C34	Trachea,Bronchus,Lung	7	%1.70	0.8	0.9	1	%1.10	0.5	0.6	0	%0.00	0	0
C37-C38	Other Thoracic organs	1	%0.20	0.1	0.1	1	%1.10	0.5	0.3	0	%0.00	0	0
C40-C41	Bone	8	%1.90	0.9	0.9	0	%0.00	0	0	2	%1.00	0.3	0.3
C43	Melanoma of Skin	0	%0.00	0	0	0	%0.00	0	0	1	%0.50	0.2	0.2
C44	Other Skin	9	%2.20	1	0.9	5	%5.50	2.4	2.2	11	%5.60	1.8	2.2
C45	Mesothelioma	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C46	Kaposi sarcoma	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C47;C49	Connective,Soft tissue	6	%1.40	0.6	0.8	1	%1.10	0.5	0.5	0	%0.00	0	0
C50	Breast	115	%27.80	12.3	13.7	30	%33.00	14.3	14.1	61	%31.00	9.7	10.7
C51	Vulva	4	%1.00	0.4	0.5	0	%0.00	0	0	0	%0.00	0	0
C52	Vagina	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C53	Cervix Uteri	5	%1.20	0.5	0.6	5	%5.50	2.4	2.5	2	%1.00	0.3	0.4
C54	Corpus Uteri	18	%4.30	1.9	2.5	13	%14.30	6.2	6.7	14	%7.10	2.2	2.8
C55	Uterus unspec.	4	%1.00	0.4	0.5	0	%0.00	0	0	0	%0.00	0	0
C56	Ovary	15	%3.60	1.6	1.7	2	%2.20	1	1	8	%4.10	1.3	1.6
C57	Other Female Genital	5	%1.20	0.5	0.6	0	%0.00	0	0	1	%0.50	0.2	0.2
C58	Placenta	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C64	Kidney	9	%2.20	1	1.1	1	%1.10	0.5	0.7	2	%1.00	0.3	0.4
C65	Renal Pelvis	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C66	Ureter	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C67	Bladder	5	%1.20	0.5	0.6	2	%2.20	1	1	3	%1.50	0.5	0.6
C68	Other Urinary organs	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C69	Eye	1	%0.20	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C70-C72	Brain, Nervous system	8	%1.90	0.9	1	2	%2.20	1	0.9	1	%0.50	0.2	0.2
C73	Thyroid	39	%9.40	4.2	4.3	4	%4.40	1.9	1.6	10	%5.10	1.6	1.6
C74	Adrenal gland	1	%0.20	0.1	0.1	0	%0.00	0	0	2	%1.00	0.3	0.4
C75	Other Endocrine	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C81	Hodgkin disease	8	%1.90	0.9	0.9	2	%2.20	1	0.9	7	%3.60	1.1	1.1
C82-C85;C96	Non-Hodgkin lymphoma	29	%7.00	3.1	3.6	2	%2.20	1	1	8	%4.10	1.3	1.7
C88	Immunoproliferative dis.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C90	Multiple Myeloma	1	%0.20	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C91	Lymphoid Leukaemia	4	%1.00	0.4	0.4	1	%1.10	0.5	0.6	1	%0.50	0.2	0.2
C92-C94	Myeloid Leukaemia	10	%2.40	1.1	1.1	1	%1.10	0.5	0.5	1	%0.50	0.2	0.2
C95	Leukaemia unspec.	7	%1.70	0.8	0.8	1	%1.10	0.5	0.6	4	%2.00	0.6	0.7
Other	Other & unspecified	4	%1.00	0.4	0.5	0	%0.00	0	0	1	%0.50	0.2	0.2
		----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	414	%100.00	44.4	50	91	%100.00	43.5	43.7	197	%100.00	31.4	36.9
Not C44	All sites but C44	405	%97.80	43.5	49.1	86	%94.50	41.1	41.4	186	%94.40	29.6	34.7

Table 5.3.2: Number Of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardised Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site, Age Groups and Regions 2020

ICD (10th)	Site	Madinah				Hail				Qassim			
		All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World
C00	Lip	1	%0.20	0.1	0.3	0	%0.00	0	0	0	%0.00	0	0
C01-C02	Tongue	0	%0.00	0	0	0	%0.00	0	0	1	%0.30	0.2	0.2
C03-C06	Mouth	0	%0.00	0	0	1	%0.60	0.3	0.4	2	%0.60	0.4	0.5
C07-C08	Salivary glands	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C09	Tonsil	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C10	Other Oropharynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C11	Nasopharynx	0	%0.00	0	0	0	%0.00	0	0	3	%0.90	0.6	0.6
C12-C13	Hypopharynx	2	%0.50	0.3	0.3	0	%0.00	0	0	0	%0.00	0	0
C14	Pharynx unspec.	0	%0.00	0	0	0	%0.00	0	0	1	%0.30	0.2	0.3
C15	Oesophagus	4	%0.90	0.6	0.8	1	%0.60	0.3	0.4	1	%0.30	0.2	0.3
C16	Stomach	6	%1.40	0.8	0.9	2	%1.20	0.7	0.6	4	%1.20	0.8	0.9
C17	Small intestine	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C18	Colon	27	%6.30	3.7	5	13	%7.60	4.5	6	42	%12.40	8	10.3
C19-C20	Rectum	10	%2.30	1.4	1.7	6	%3.50	2.1	2.5	10	%3.00	1.9	2.2
C21	Anus	1	%0.20	0.1	0.2	1	%0.60	0.3	0.4	0	%0.00	0	0
C22	Liver	11	%2.60	1.5	2.1	4	%2.30	1.4	2	6	%1.80	1.1	1.7
C23-C24	Gallbladder etc.	7	%1.60	1	1.4	4	%2.30	1.4	1.8	5	%1.50	1	1.2
C25	Pancreas	7	%1.60	1	1.4	2	%1.20	0.7	0.7	4	%1.20	0.8	1
C30-C31	Nose, sinuses etc.	1	%0.20	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C32	Larynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C33-C34	Trachea,Bronchus,Lung	4	%0.90	0.6	0.7	1	%0.60	0.3	0.2	4	%1.20	0.8	1.1
C37-C38	Other Thoracic organs	0	%0.00	0	0	1	%0.60	0.3	0.3	1	%0.30	0.2	0.1
C40-C41	Bone	1	%0.20	0.1	0.3	1	%0.60	0.3	0.3	3	%0.90	0.6	0.5
C43	Melanoma of Skin	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C44	Other Skin	2	%0.50	0.3	0.3	2	%1.20	0.7	0.7	1	%0.30	0.2	0.4
C45	Mesothelioma	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C46	Kaposi sarcoma	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C47;C49	Connective,Soft tissue	6	%1.40	0.8	1.1	3	%1.70	1	1.2	5	%1.50	1	0.9
C50	Breast	138	%32.10	19.1	23.2	45	%26.20	15.7	18.1	119	%35.20	22.7	28.1
C51	Vulva	2	%0.50	0.3	0.3	0	%0.00	0	0	0	%0.00	0	0
C52	Vagina	1	%0.20	0.1	0.3	0	%0.00	0	0	0	%0.00	0	0
C53	Cervix Uteri	5	%1.20	0.7	0.8	2	%1.20	0.7	0.9	4	%1.20	0.8	0.9
C54	Corpus Uteri	23	%5.30	3.2	5.2	6	%3.50	2.1	2.4	24	%7.10	4.6	6.3
C55	Uterus unspec.	2	%0.50	0.3	0.5	0	%0.00	0	0	3	%0.90	0.6	0.8
C56	Ovary	18	%4.20	2.5	3.5	2	%1.20	0.7	1.2	10	%3.00	1.9	2.4
C57	Other Female Genital	0	%0.00	0	0	2	%1.20	0.7	0.9	4	%1.20	0.8	1
C58	Placenta	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C64	Kidney	11	%2.60	1.5	2	2	%1.20	0.7	0.8	9	%2.70	1.7	2.3
C65	Renal Pelvis	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C66	Ureter	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C67	Bladder	6	%1.40	0.8	1.4	1	%0.60	0.3	0.4	3	%0.90	0.6	0.7
C68	Other Urinary organs	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C69	Eye	1	%0.20	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C70-C72	Brain, Nervous system	16	%3.70	2.2	3	4	%2.30	1.4	1.3	9	%2.70	1.7	2
C73	Thyroid	29	%6.70	4	3.9	40	%23.30	14	14.6	26	%7.70	5	5.1
C74	Adrenal gland	1	%0.20	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C75	Other Endocrine	1	%0.20	0.1	0.1	0	%0.00	0	0	0	%0.00	0	0
C81	Hodgkin disease	10	%2.30	1.4	1.3	6	%3.50	2.1	1.9	9	%2.70	1.7	1.7
C82-C85;C96	Non-Hodgkin lymphoma	15	%3.50	2.1	2.2	8	%4.70	2.8	3.4	10	%3.00	1.9	2.1
C88	Immunoproliferative dis.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C90	Multiple Myeloma	3	%0.70	0.4	0.5	1	%0.60	0.3	0.5	3	%0.90	0.6	0.7
C91	Lymphoid Leukaemia	6	%1.40	0.8	1	3	%1.70	1	1.1	2	%0.60	0.4	0.4
C92-C94	Myeloid Leukaemia	5	%1.20	0.7	0.6	3	%1.70	1	0.8	3	%0.90	0.6	0.6
C95	Leukaemia unspec.	32	%7.40	4.4	5.1	1	%0.60	0.3	0.3	2	%0.60	0.4	0.5
Other	Other & unspecified	15	%3.50	2.1	3	4	%2.30	1.4	1.5	5	%1.50	1	1.1
		----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	430	%100.00	59.6	74.8	172	%100.00	60.1	67.7	338	%100.00	64.5	78.9
Not C44	All sites but C44	428	%99.50	59.3	74.5	170	%98.80	59.4	67	337	%99.70	64.3	78.5

Table 5.3.3: Number Of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardised Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site, Age Groups and Regions 2020

ICD (10th)	Site	Najran				Jouf				Tabuk				Northern Region			
		All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World
C00	Lip	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C01-C02	Tongue	0	%0.00	0	0	1	%0.90	0.5	1.2	3	%1.30	0.8	1.3	1	%1.20	0.7	1
C03-C06	Mouth	0	%0.00	0	0	2	%1.70	1	1.5	1	%0.40	0.3	0.3	0	%0.00	0	0
C07-C08	Salivary glands	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C09	Tonsil	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C10	Other Oropharynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C11	Nasopharynx	1	%0.70	0.4	0.6	1	%0.90	0.5	0.7	4	%1.70	1.1	1.5	2	%2.50	1.3	2
C12-C13	Hypopharynx	0	%0.00	0	0	1	%0.90	0.5	0.4	0	%0.00	0	0	0	%0.00	0	0
C14	Pharynx unspec.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C15	Oesophagus	1	%0.70	0.4	0.8	1	%0.90	0.5	0.8	1	%0.40	0.3	0.7	0	%0.00	0	0
C16	Stomach	4	%2.80	1.7	2.7	0	%0.00	0	0	2	%0.80	0.5	0.8	0	%0.00	0	0
C17	Small intestine	0	%0.00	0	0	1	%0.90	0.5	1.1	1	%0.40	0.3	0.6	0	%0.00	0	0
C18	Colon	7	%5.00	3.1	5.2	7	%6.00	3.6	5.1	8	%3.40	2.2	3.5	2	%2.50	1.3	1.6
C19-C20	Rectum	2	%1.40	0.9	0.6	4	%3.40	2	3.9	6	%2.50	1.6	1.9	4	%5.00	2.6	3.2
C21	Anus	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C22	Liver	4	%2.80	1.7	2.9	4	%3.40	2	3	6	%2.50	1.6	2.8	3	%3.80	2	2.5
C23-C24	Gallbladder etc.	0	%0.00	0	0	4	%3.40	2	3.1	1	%0.40	0.3	0.7	2	%2.50	1.3	2.4
C25	Pancreas	0	%0.00	0	0	1	%0.90	0.5	0.7	3	%1.30	0.8	1.5	3	%3.80	2	3.2
C30-C31	Nose, sinuses etc.	0	%0.00	0	0	0	%0.00	0	0	1	%0.40	0.3	0.4	0	%0.00	0	0
C32	Larynx	0	%0.00	0	0	0	%0.00	0	0	1	%0.40	0.3	0.5	0	%0.00	0	0
C33-C34	Trachea,Bronchus,Lung	0	%0.00	0	0	2	%1.70	1	1.8	3	%1.30	0.8	1.5	4	%5.00	2.6	4.4
C37-C38	Other Thoracic organs	0	%0.00	0	0	0	%0.00	0	0	1	%0.40	0.3	0.3	0	%0.00	0	0
C40-C41	Bone	1	%0.70	0.4	0.4	0	%0.00	0	0	4	%1.70	1.1	1.4	0	%0.00	0	0
C43	Melanoma of Skin	1	%0.70	0.4	0.8	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C44	Other Skin	4	%2.80	1.7	2.5	3	%2.60	1.5	3.3	5	%2.10	1.4	2.5	0	%0.00	0	0
C45	Mesothelioma	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C46	Kaposi sarcoma	0	%0.00	0	0	0	%0.00	0	0	1	%0.40	0.3	0.4	0	%0.00	0	0
C47,C49	Connective,Soft tissue	3	%2.10	1.3	1.1	0	%0.00	0	0	1	%0.40	0.3	0.4	0	%0.00	0	0
C50	Breast	28	%19.90	12.2	13.6	34	%29.10	17.3	25.2	62	%26.10	16.7	20.8	14	%17.50	9.2	11
C51	Vulva	1	%0.70	0.4	0.3	0	%0.00	0	0	1	%0.40	0.3	0.4	0	%0.00	0	0
C52	Vagina	0	%0.00	0	0	0	%0.00	0	0	1	%0.40	0.3	0.6	0	%0.00	0	0
C53	Cervix Uteri	0	%0.00	0	0	1	%0.90	0.5	0.5	2	%0.80	0.5	0.5	0	%0.00	0	0
C54	Corpus Uteri	3	%2.10	1.3	2.5	6	%5.10	3	6	2	%0.80	0.5	1.1	4	%5.00	2.6	3.7
C55	Uterus unspec.	3	%2.10	1.3	2.7	3	%2.60	1.5	2.1	5	%2.10	1.4	2	1	%1.20	0.7	1
C56	Ovary	6	%4.30	2.6	3.9	4	%3.40	2	2.6	11	%4.60	3	4.2	2	%2.50	1.3	1.7
C57	Other Female Genital	1	%0.70	0.4	0.9	0	%0.00	0	0	1	%0.40	0.3	0.5	0	%0.00	0	0
C58	Placenta	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C64	Kidney	1	%0.70	0.4	0.4	1	%0.90	0.5	0.7	3	%1.30	0.8	0.7	1	%1.20	0.7	0.6
C65	Renal Pelvis	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C66	Ureter	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C67	Bladder	3	%2.10	1.3	2.2	0	%0.00	0	0	4	%1.70	1.1	1.8	1	%1.20	0.7	0.5
C68	Other Urinary organs	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C69	Eye	0	%0.00	0	0	1	%0.90	0.5	0.4	0	%0.00	0	0	1	%1.20	0.7	1
C70-C72	Brain, Nervous system	3	%2.10	1.3	1	3	%2.60	1.5	1.4	6	%2.50	1.6	1.9	3	%3.80	2	2.3
C73	Thyroid	33	%23.40	14.4	15.5	10	%8.50	5.1	6	44	%18.50	11.9	13.2	12	%15.00	7.9	8.7
C74	Adrenal gland	0	%0.00	0	0	1	%0.90	0.5	0.5	0	%0.00	0	0	1	%1.20	0.7	1.3
C75	Other Endocrine	1	%0.70	0.4	0.6	0	%0.00	0	0	0	%0.00	0	0	1	%1.20	0.7	0.5
C81	Hodgkin disease	6	%4.30	2.6	2.5	4	%3.40	2	1.9	12	%5.00	3.2	3.5	4	%5.00	2.6	2.2
C82-C85,C96	Non-Hodgkin lymphoma	8	%5.70	3.5	4.9	5	%4.30	2.5	3.1	15	%6.30	4.1	5.1	2	%2.50	1.3	2
C88	Immunoproliferative dis.	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C90	Multiple Myeloma	2	%1.40	0.9	1.4	1	%0.90	0.5	1	3	%1.30	0.8	1.3	1	%1.20	0.7	1
C91	Lymphoid Leukaemia	2	%1.40	0.9	0.9	5	%4.30	2.5	2.2	3	%1.30	0.8	0.9	2	%2.50	1.3	1.6
C92-C94	Myeloid Leukaemia	5	%3.50	2.2	2.7	4	%3.40	2	1.6	3	%1.30	0.8	0.8	7	%8.80	4.6	5.5
C95	Leukaemia unspec.	3	%2.10	1.3	1.4	1	%0.90	0.5	0.4	2	%0.80	0.5	0.5	2	%2.50	1.3	2.4
Other	Other & unspecified	4	%2.80	1.7	2	1	%0.90	0.5	0.4	5	%2.10	1.4	1.8	0	%0.00	0	0
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
All	All sites Total	141	%100.00	61.5	76.9	117	%100.00	59.4	82.6	238	%100.00	64.3	84.4	80	%100.00	52.6	67.3
Not C44	All sites but C44	137	%97.20	59.8	74.4	114	%97.40	57.9	79.3	233	%97.90	62.9	81.9	80	%100.00	52.6	67.3

Table 5.3.4: Number Of Cases, Relative Frequency, Crude Incidence Rate (CIR) Age-Standardised Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site, Age Groups and Regions 2020

ICD (10th)	Site	Riyadh				Makkah				Eastern Province			
		All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World	All Ages	Total (%)	Crude Rate	ASR World
C00	Lip	1	%0.00	0	0.1	4	%0.30	0.2	0.2	0	%0.00	0	0
C01-C02	Tongue	17	%0.70	0.7	1.2	8	%0.50	0.3	0.4	6	%0.40	0.4	0.6
C03-C06	Mouth	12	%0.50	0.5	0.8	2	%0.10	0.1	0.1	4	%0.30	0.3	0.5
C07-C08	Salivary glands	4	%0.20	0.2	0.3	3	%0.20	0.1	0.2	4	%0.30	0.3	0.3
C09	Tonsil	1	%0.00	0	0.1	0	%0.00	0	0	1	%0.10	0.1	0
C10	Other Oropharynx	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C11	Nasopharynx	29	%1.10	1.2	1.5	11	%0.70	0.5	0.5	4	%0.30	0.3	0.4
C12-C13	Hypopharynx	1	%0.00	0	0.1	2	%0.10	0.1	0.1	0	%0.00	0	0
C14	Pharynx unspec.	1	%0.00	0	0.1	0	%0.00	0	0	1	%0.10	0.1	0.1
C15	Oesophagus	6	%0.20	0.3	0.4	9	%0.60	0.4	0.5	4	%0.30	0.3	0.4
C16	Stomach	40	%1.50	1.7	2.6	27	%1.70	1.2	1.4	21	%1.40	1.3	1.8
C17	Small intestine	9	%0.30	0.4	0.6	7	%0.40	0.3	0.4	8	%0.50	0.5	0.8
C18	Colon	163	%6.30	6.9	10.2	126	%8.00	5.4	6.6	84	%5.80	5.3	8.1
C19-C20	Rectum	94	%3.60	4	6.3	50	%3.20	2.1	2.6	42	%2.90	2.6	4
C21	Anus	2	%0.10	0.1	0.1	5	%0.30	0.2	0.3	2	%0.10	0.1	0.2
C22	Liver	43	%1.70	1.8	3.4	41	%2.60	1.7	2.3	20	%1.40	1.3	2.2
C23-C24	Gallbladder etc.	36	%1.40	1.5	2.7	13	%0.80	0.6	0.6	8	%0.50	0.5	0.8
C25	Pancreas	35	%1.40	1.5	2.6	38	%2.40	1.6	2.1	27	%1.90	1.7	2.8
C30-C31	Nose, sinuses etc.	6	%0.20	0.3	0.4	5	%0.30	0.2	0.2	3	%0.20	0.2	0.3
C32	Larynx	3	%0.10	0.1	0.2	2	%0.10	0.1	0.1	1	%0.10	0.1	0.1
C33-C34	Trachea,Bronchus,Lung	34	%1.30	1.4	2.3	19	%1.20	0.8	1.1	26	%1.80	1.6	2.3
C37-C38	Other Thoracic organs	4	%0.20	0.2	0.2	9	%0.60	0.4	0.4	5	%0.30	0.3	0.4
C40-C41	Bone	32	%1.20	1.4	1.4	30	%1.90	1.3	1.4	8	%0.50	0.5	0.5
C43	Melanoma of Skin	2	%0.10	0.1	0.2	0	%0.00	0	0	4	%0.30	0.3	0.3
C44	Other Skin	23	%0.90	1	1.5	14	%0.90	0.6	0.7	9	%0.60	0.6	0.7
C45	Mesothelioma	1	%0.00	0	0	1	%0.10	0	0	1	%0.10	0.1	0.1
C46	Kaposi sarcoma	5	%0.20	0.2	0.3	0	%0.00	0	0	0	%0.00	0	0
C47,C49	Connective,Soft tissue	31	%1.20	1.3	1.6	13	%0.80	0.6	0.6	17	%1.20	1.1	1.2
C50	Breast	745	%28.80	31.5	43.3	515	%32.80	22	24.9	551	%37.80	34.7	46.2
C51	Vulva	5	%0.20	0.2	0.2	0	%0.00	0	0	3	%0.20	0.2	0.2
C52	Vagina	1	%0.00	0	0.1	2	%0.10	0.1	0.1	0	%0.00	0	0
C53	Cervix Uteri	62	%2.40	2.6	3.6	31	%2.00	1.3	1.6	16	%1.10	1	1.2
C54	Corpus Uteri	172	%6.60	7.3	13	102	%6.50	4.4	5.7	106	%7.30	6.7	11.6
C55	Uterus unspec.	63	%2.40	2.7	4.1	18	%1.10	0.8	1.1	16	%1.10	1	1.7
C56	Ovary	75	%2.90	3.2	4.4	38	%2.40	1.6	1.9	43	%2.90	2.7	3.6
C57	Other Female Genital	10	%0.40	0.4	0.6	5	%0.30	0.2	0.3	5	%0.30	0.3	0.5
C58	Placenta	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C64	Kidney	46	%1.80	1.9	2.8	27	%1.70	1.2	1.3	37	%2.50	2.3	3.5
C65	Renal Pelvis	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C66	Ureter	0	%0.00	0	0	0	%0.00	0	0	0	%0.00	0	0
C67	Bladder	13	%0.50	0.6	1	7	%0.40	0.3	0.4	9	%0.60	0.6	0.7
C68	Other Urinary organs	1	%0.00	0	0.1	0	%0.00	0	0	0	%0.00	0	0
C69	Eye	10	%0.40	0.4	0.5	2	%0.10	0.1	0.1	2	%0.10	0.1	0.1
C70-C72	Brain, Nervous system	77	%3.00	3.3	3.9	45	%2.90	1.9	2.1	27	%1.90	1.7	2.1
C73	Thyroid	330	%12.70	14	15.8	100	%6.40	4.3	4.3	139	%9.50	8.8	9.7
C74	Adrenal gland	7	%0.30	0.3	0.4	6	%0.40	0.3	0.3	2	%0.10	0.1	0.1
C75	Other Endocrine	0	%0.00	0	0	1	%0.10	0	0.1	1	%0.10	0.1	0.1
C81	Hodgkin disease	60	%2.30	2.5	2.6	52	%3.30	2.2	2.3	54	%3.70	3.4	3.3
C82-C85,C96	Non-Hodgkin lymphoma	110	%4.20	4.7	6.3	74	%4.70	3.2	3.7	50	%3.40	3.2	4.5
C88	Immunoproliferative dis.	0	%0.00	0	0	0	%0.00	0	0	1	%0.10	0.1	0.1
C90	Multiple Myeloma	31	%1.20	1.3	2.3	10	%0.60	0.4	0.5	14	%1.00	0.9	1.4
C91	Lymphoid Leukaemia	26	%1.00	1.1	1.2	17	%1.10	0.7	0.8	12	%0.80	0.8	1
C92-C94	Myeloid Leukaemia	55	%2.10	2.3	3	21	%1.30	0.9	1	38	%2.60	2.4	2.8
C95	Leukaemia unspec.	25	%1.00	1.1	1.2	15	%1.00	0.6	0.8	6	%0.40	0.4	0.5
Other	Other & unspecified	31	%1.20	1.3	1.9	43	%2.70	1.8	2.2	16	%1.10	1	1.6
		----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	2590	%100.00	109.6	153.5	1570	%100.00	67	78.5	1458	%100.00	91.9	125.5
Not C44	All sites but C44	2567	%99.10	108.6	152	1556	%99.10	66.4	77.8	1449	%99.40	91.4	124.8

Table 5.4.1: Number Of Cases Among Non-Saudi Males by Primary Site And Age Groups, 2020

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)	
C00	Lip	9	0	0	0	0	0	0	0	1	3	2	0	0	0	1	1	0	1	%0.50	
C01-C02	Tongue	22	1	0	0	0	0	0	1	1	5	2	4	3	4	1	0	0	0	%1.30	
C03-C06	Mouth	15	1	0	0	0	0	0	0	2	0	3	4	0	1	3	0	0	1	%0.90	
C07-C08	Salivary glands	9	0	0	0	0	0	0	1	0	1	0	1	0	1	5	0	0	0	%0.50	
C09	Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	%0.10	
C10	Other Oropharynx	2	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	%0.10	
C11	Nasopharynx	36	0	0	1	0	0	2	2	3	8	6	1	4	7	1	1	0	0	%2.20	
C12-C13	Hypopharynx	3	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	%0.20	
C14	Pharynx unspec.	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	%0.20	
C15	Oesophagus	22	0	0	0	0	0	0	2	1	0	1	1	3	3	5	2	0	4	%1.30	
C16	Stomach	60	1	0	0	0	0	0	1	4	4	6	11	4	7	11	4	4	3	%3.60	
C17	Small intestine	15	1	0	0	0	0	1	0	2	3	3	0	1	1	1	0	1	1	%0.90	
C18	Colon	167	4	0	0	0	0	1	2	9	11	19	19	19	21	20	18	14	10	%10.00	
C19-C20	Rectum	89	2	0	0	0	0	0	3	4	4	12	7	12	21	11	5	6	2	%5.30	
C21	Anus	6	0	0	0	0	0	0	0	0	0	1	2	1	0	1	1	0	0	%0.40	
C22	Liver	50	0	0	0	0	0	0	3	2	3	5	1	4	7	9	4	9	3	%3.00	
C23-C24	Gallbladder etc.	16	0	0	0	0	0	0	0	0	5	0	2	4	3	0	2	0	0	%1.00	
C25	Pancreas	35	0	0	0	0	0	0	0	0	2	3	2	2	8	7	5	3	3	%2.10	
C30-C31	Nose, sinuses etc.	6	0	0	0	0	0	0	0	0	0	0	1	3	1	0	1	0	0	%0.40	
C32	Larynx	23	1	0	0	0	0	0	0	0	1	2	1	6	2	3	4	1	2	%1.40	
C33-C34	Trachea,Bronchus,Lung	107	5	0	0	0	0	2	0	2	5	8	5	15	17	13	17	12	6	%6.40	
C37-C38	Other Thoracic organs	14	0	0	0	0	0	0	1	4	2	2	1	1	0	2	0	1	0	%0.80	
C40-C41	Bone	45	0	1	2	4	6	0	2	3	2	6	3	5	2	2	2	3	2	%2.70	
C43	Melanoma of Skin	8	1	0	0	0	0	0	0	1	0	0	2	2	0	0	1	1	0	%0.50	
C44	Other Skin	69	1	0	0	0	0	2	0	4	3	4	5	13	5	11	8	7	6	%4.10	
C45	Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	%0.10	
C46	Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	%0.10	
C47;C49	Connective,Soft tissue	40	1	2	1	1	0	4	4	3	4	2	2	3	7	4	0	0	2	%2.40	
C50	Breast	12	0	0	0	0	0	0	0	0	1	3	1	3	2	0	1	1	0	%0.70	
C60	Penis	3	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	%0.20	
C61	Prostate	89	7	0	0	0	0	0	0	0	0	0	1	5	9	18	25	11	13	%5.30	
C62	Testis	23	1	2	0	0	1	0	4	4	3	2	2	1	1	1	0	0	1	%1.40	
C63	Other male genital	2	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	%0.10	
C64	Kidney	54	1	0	1	0	0	1	1	4	3	5	7	6	8	9	5	3	0	%3.20	
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00	
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00	
C67	Bladder	83	1	2	0	0	0	0	0	2	3	1	10	12	10	19	10	6	7	%5.00	
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	%0.10	
C69	Eye	6	0	4	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	%0.40	
C70-C72	Brain, Nervous system	72	4	2	6	6	2	0	3	7	6	6	11	6	8	4	0	0	1	%4.30	
C73	Thyroid	55	0	0	0	0	0	1	3	9	7	10	5	7	3	7	1	1	1	%3.30	
C74	Adrenal gland	4	0	1	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	%0.20	
C75	Other Endocrine	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	%0.10	
C81	Hodgkin disease	54	1	0	7	6	4	2	4	7	9	3	4	3	3	0	0	0	1	%3.20	
C82-C85;C96	Non-Hodgkin lymphoma	103	3	1	2	2	3	2	5	8	12	6	15	10	7	9	7	7	4	%6.20	
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00	
C90	Multiple Myeloma	31	0	0	0	0	0	0	0	1	4	2	6	5	4	3	4	1	1	%1.90	
C91	Lymphoid Leukaemia	69	0	8	24	4	2	2	4	6	4	3	1	0	5	5	1	0	0	%4.10	
C92-C94	Myeloid Leukaemia	49	1	2	0	4	1	2	2	9	8	4	5	5	1	1	4	0	0	%2.90	
C95	Leukaemia unspec.	37	0	10	2	2	2	0	2	3	6	1	5	1	0	2	0	1	0	%2.20	
Other	Other & unspecified	47	1	1	0	0	0	0	1	3	5	8	6	5	6	3	2	4	2	%2.80	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	1669	39	36	46	29	21	22	51	111	139	144	158	178	189	192	137	99	78	%100.00	
Not C44	All sites but C44	1600	38	36	46	29	21	20	51	107	136	140	153	165	184	181	129	92	72	%95.90	

Table 5.4.2: Number Of Cases Among Non-Saudi Females by Primary Site And Age Groups, 2020

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	%60.20
C01-C02	Tongue	12	0	0	0	0	0	0	1	0	0	3	0	6	1	1	0	0	0	%60.80
C03-C06	Mouth	2	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	%60.10
C07-C08	Salivary glands	4	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	1	%60.30
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C10	Other Oropharynx	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	%60.10
C11	Nasopharynx	4	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	1	%60.30
C12-C13	Hypopharynx	4	0	0	0	0	0	0	1	1	0	1	0	0	1	0	0	0	0	%60.30
C14	Pharynx unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C15	Oesophagus	11	1	0	0	0	0	0	2	2	2	0	0	0	2	0	0	1	1	%60.70
C16	Stomach	24	1	1	0	0	0	0	0	5	5	6	0	1	1	2	0	1	1	%61.50
C17	Small intestine	5	0	0	0	0	0	0	0	1	0	0	2	1	0	0	1	0	0	%60.30
C18	Colon	75	5	0	0	0	0	3	2	5	3	7	8	5	7	16	2	8	4	%64.80
C19-C20	Rectum	24	1	0	0	0	0	0	1	1	1	0	6	3	3	3	3	2	0	%61.50
C21	Anus	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	%60.10
C22	Liver	13	1	0	0	0	0	0	0	0	1	1	1	0	4	0	1	2	2	%60.80
C23-C24	Gallbladder etc.	10	0	0	0	0	0	0	0	0	0	0	1	0	3	1	3	2	0	%60.60
C25	Pancreas	23	2	0	0	0	0	0	0	1	1	0	4	3	6	1	2	1	2	%61.50
C30-C31	Nose, sinuses etc.	5	0	0	0	0	0	0	0	0	3	0	0	0	0	1	1	0	0	%60.30
C32	Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	%60.10
C33-C34	Trachea,Bronchus,Lung	30	2	0	0	0	0	0	1	2	2	2	3	3	1	4	5	3	2	%61.90
C37-C38	Other Thoracic organs	4	0	0	0	0	0	0	0	0	1	0	1	0	1	1	0	0	0	%60.30
C40-C41	Bone	30	0	3	2	4	1	1	1	0	2	4	1	2	0	3	3	1	2	%61.90
C43	Melanoma of Skin	5	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	2	%60.30
C44	Other Skin	24	0	0	0	1	0	0	1	1	1	4	2	4	1	2	2	2	3	%61.50
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C46	Kaposi sarcoma	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	%60.10
C47;C49	Connective,Soft tissue	28	1	0	3	1	0	2	2	5	2	2	1	3	1	3	0	1	1	%61.80
C50	Breast	646	8	0	0	0	0	1	18	55	96	111	93	81	62	50	36	20	15	%41.10
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C52	Vagina	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	%60.10
C53	Cervix Uteri	36	0	0	0	0	0	0	0	6	2	3	12	4	2	2	0	4	1	%62.30
C54	Corpus Uteri	64	0	0	0	0	0	0	1	5	1	8	5	5	12	8	12	2	5	%64.10
C55	Uterus unspec.	20	0	0	0	0	0	0	0	0	2	5	3	2	1	3	1	1	2	%61.30
C56	Ovary	45	0	0	1	1	1	0	2	4	11	4	7	10	1	0	2	1	0	%62.90
C57	Other Female Genital	6	0	0	0	0	0	0	1	0	0	1	0	2	0	0	0	1	1	%60.40
C58	Placenta	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	%60.10
C64	Kidney	16	0	0	1	0	0	1	0	0	1	0	4	2	3	2	0	1	1	%61.00
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C67	Bladder	13	0	0	0	0	0	0	0	1	0	0	0	2	5	2	0	3	0	%60.80
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C69	Eye	2	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	%60.10
C70-C72	Brain, Nervous system	39	0	2	5	4	0	4	3	2	2	2	4	3	2	2	3	0	1	%62.50
C73	Thyroid	116	3	0	0	0	3	5	11	25	22	18	8	12	3	4	0	0	2	%67.40
C74	Adrenal gland	2	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	%60.10
C75	Other Endocrine	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.10
C81	Hodgkin disease	34	2	1	2	1	3	3	5	6	3	1	2	2	2	0	0	0	1	%62.20
C82-C85;C96	Non-Hodgkin Lymphoma	40	1	0	1	0	2	2	0	6	3	5	3	8	5	0	1	3	0	%62.50
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C90	Multiple Myeloma	14	0	0	0	0	0	0	0	0	1	0	2	3	3	0	3	1	1	%60.90
C91	Lymphoid Leukaemia	33	0	7	17	4	2	1	0	0	1	1	0	0	0	0	0	0	0	%62.10
C92-C94	Myeloid Leukaemia	27	0	1	2	1	2	1	2	0	1	3	2	4	2	1	2	1	2	%61.70
C95	Leukaemia unspec.	17	0	5	3	0	1	0	0	0	1	0	1	1	1	1	2	1	0	%61.10
Other	Other & unspecified	53	0	1	0	1	0	0	1	2	5	9	5	10	11	4	0	2	2	%63.40
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	1572	28	22	39	18	15	24	57	140	179	203	184	184	152	119	87	65	56	%100.00
Not C44	All sites but C44	1548	28	22	39	17	15	24	56	139	178	199	182	180	151	117	85	63	53	%98.50

Table 5.4.3: Age-Specific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Non-Saudi Males (per 100,000) by Primary Site and Age groups, 2020

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World	
C00	Lip	9	0	0	0	0	0	0	0	0.1	0.2	0.1	0	0	0	0.4	1.2	0	3.1	0.1	0.1	
C01-C02	Tongue	22	1	0	0	0	0	0	0.1	0.1	0.3	0.1	0.4	0.4	0.9	0.4	0	0	0	0.2	0.1	
C03-C06	Mouth	15	1	0	0	0	0	0	0	0.2	0	0.2	0.4	0	0.2	1.2	0	0	3.1	0.2	0.2	
C07-C08	Salivary glands	9	0	0	0	0	0	0	0.1	0	0.1	0	0.1	0	0.2	2.1	0	0	0	0.1	0.1	
C09	Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	
C10	Other Oropharynx	2	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0	0	0	0	0	0	
C11	Nasopharynx	36	0	0	0.2	0	0	0.6	0.2	0.3	0.5	0.4	0.1	0.5	1.6	0.4	1.2	0	0	0.4	0.3	
C12-C13	Hypopharynx	3	0	0	0	0	0	0	0	0	0.1	0	0	0.1	0.2	0	0	0	0	0	0	
C14	Pharynx unspec.	3	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	2.6	3.1+	0	0.1	
C15	Oesophagus	22	0	0	0	0	0	0	0.2	0.1	0	0.1	0.1	0.4	0.7	2.1	2.4	0	12.5	0.2	0.5	
C16	Stomach	60	1	0	0	0	0	0	0.1	0.4	0.3	0.4	1	0.5	1.6	4.6	4.8	10.5	9.4	0.6	1	
C17	Small intestine	15	1	0	0	0	0	0.3	0	0.2	0.2	0.2	0	0.1	0.2	0.4	0	2.6	3.1	0.2	0.2	
C18	Colon	167	4	0	0	0	0	0.3	0.2	0.8	0.7	1.3	1.7	2.5	4.7	8.3	21.6	36.7	31.3	1.8	3	
C19-C20	Rectum	89	2	0	0	0	0	0	0.4	0.4	0.3	0.8	0.6	1.6	4.7	4.6	6	15.7	6.3	1	1.3	
C21	Anus	6	0	0	0	0	0	0	0	0	0	0.1	0.2	0.1	0	0.4	1.2	0	0	0.1	0.1	
C22	Liver	50	0	0	0	0	0	0	0.4	0.2	0.2	0.3	0.1	0.5	1.6	3.7	4.8	23.6	9.4	0.5	1.1	
C23-C24	Gallbladder etc.	16	0	0	0	0	0	0	0	0	0.3	0	0.2	0.5	0.7	0	2.4	0	0	0.2	0.2	
C25	Pancreas	35	0	0	0	0	0	0	0	0	0.1	0.2	0.2	0.3	1.8	2.9	6	7.9	9.4	0.4	0.8	
C30-C31	Nose, sinuses etc.	6	0	0	0	0	0	0	0	0	0	0	0.1	0.4	0.2	0	1.2	0	0	0.1	0.1	
C32	Larynx	23	1	0	0	0	0	0	0	0	0.1	0.1	0.1	0.8	0.4	1.2	4.8	2.6	6.3	0.2	0.5	
C33-C34	Trachea,Bronchus,Lung	107	5	0	0	0	0	0.6	0	0.2	0.3	0.5	0.5	2	3.8	5.4	20.4	31.5	18.8	1.1	2.3	
C37-C38	Other Thoracic organs	14	0	0	0	0	0	0	0.1	0.4	0.1	0.1	0.1	0.1	0	0.8	0	2.6	0	0.1	0.1	
C40-C41	Bone	45	0	0.3	0.5	1.2	2.2	0	0.2	0.3	0.1	0.4	0.3	0.7	0.4	0.8	2.4	7.9	6.3	0.5	0.9	
C43	Melanoma of Skin	8	1	0	0	0	0	0	0	0.1	0	0	0.2	0.3	0	0	1.2	2.6	0	0.1	0.1	
C44	Other Skin	69	1	0	0	0	0	0.6	0	0.4	0.2	0.3	0.5	1.7	1.1	4.6	9.6	18.3	18.8	0.7	1.5	
C45	Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	
C46	Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	
C47;C49	Connective,Soft tissue	40	1	0.6	0.2	0.3	0	1.2	0.5	0.3	0.3	0.1	0.2	0.4	1.6	1.7	0	0	6.3	0.4	0.6	
C50	Breast	12	0	0	0	0	0	0	0	0	0.1	0.2	0.1	0.4	0.4	0	1.2	2.6	0	0.1	0.1	
C60	Penis	3	0	0	0	0	0	0	0	0	0.1	0	0	0.1	0	0	0	2.6	0	0	0.1	
C61	Prostate	89	7	0	0	0	0	0	0	0	0	0	0.1	0.7	2	7.5	30	28.8	40.8	1	2.9	
C62	Testis	23	1	0.6	0	0	0.4	0	0.5	0.4	0.2	0.1	0.2	0.1	0.2	0.4	0	0	3.1	0.2	0.3	
C63	Other male genital	2	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0	0	0	0	0	0	
C64	Kidney	54	1	0	0.2	0	0	0.3	0.1	0.4	0.2	0.3	0.6	0.8	1.8	3.7	6	7.9	0	0.6	0.8	
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C67	Bladder	83	1	0.6	0	0	0	0	0	0.2	0.2	0.1	0.9	1.6	2.2	7.9	12	15.7	21.9	0.9	1.8	
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	
C69	Eye	6	0	1.2	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0	0	0.1	0.2	
C70-C72	Brain, Nervous system	72	4	0.6	1.5	1.8	0.7	0	0.4	0.6	0.4	0.4	1	0.8	1.8	1.7	0	0	3.1	0.8	0.9	
C73	Thyroid	55	0	0	0	0	0	0.3	0.4	0.8	0.4	0.7	0.5	0.9	0.7	2.9	1.2	2.6	3.1	0.6	0.5	
C74	Adrenal gland	4	0	0.3	0	0	0	0	0	0	0	0.1	0	0	0.2	0	1.2	0	0	0	0.1	
C75	Other Endocrine	1	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	
C81	Hodgkin disease	54	1	0	1.7	1.8	1.5	0.6	0.5	0.6	0.6	0.2	0.4	0.4	0.7	0	0	0	3.1	0.6	0.8	
C82-C85;C96	Non-Hodgkin lymphoma	103	3	0.3	0.5	0.6	1.1	0.6	0.6	0.7	0.8	0.4	1.4	1.3	1.6	3.7	8.4	18.3	12.5	1.1	1.7	
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C90	Multiple Myeloma	31	0	0	0	0	0	0	0	0.1	0.3	0.1	0.5	0.7	0.9	1.2	4.8	2.6	3.1	0.3	0.4	
C91	Lymphoid Leukaemia	69	0	2.5	5.9	1.2	0.7	0.6	0.5	0.6	0.3	0.2	0.1	0	1.1	2.1	1.2	0	0	0.7	1.4	
C92-C94	Myeloid Leukaemia	49	1	0.6	0	1.2	0.4	0.6	0.2	0.8	0.5	0.3	0.5	0.7	0.2	0.4	4.8	0	0	0.5	0.6	
C95	Leukaemia unspec.	37	0	3.1	0.5	0.6	0.7	0	0.2	0.3	0.4	0.1	0.5	0.1	0	0.8	0	2.6	0	0.4	0.7	
Other	Other & unspecified	47	1	0.3	0	0	0	0	0.1	0.3	0.3	0.5	0.5	0.7	1.3	1.2	2.4	10.5	6.3	0.5	0.7	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	1669	39	11	11	9	8	7	6	10	9	10	14	24	42	80	164	259	245	17.9	29.3	
Not C44	All sites but C44	1600	38	11	11	9	8	6	6	10	9	9	14	22	41	75	155	241	226	17.1	27.8	

Table 5.4.4: Age-Specific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Non-Saudi Females (per 100,000) by Primary Site and Age groups, 2020

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World	
C00	Lip	3	0	0	0	0	0	0	0	0	0	0	0	0	1.3	1.9	3	0	0	0.1	0.2	
C01-C02	Tongue	12	0	0	0	0	0	0	0.2	0	0	0.5	0	5.2	1.3	1.9	0	0	0	0.3	0.4	
C03-C06	Mouth	2	0	0.3	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0.1	
C07-C08	Salivary glands	4	0	0	0	0	0	0	0.2	0.2	0	0	0.3	0	0	0	0	0	0	7.9	0.1	0.2
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Other Oropharynx	2	0	0	0	0	0	0	0	0	0	0.2	0	0	1.3	0	0	0	0	0	0	0.1
C11	Nasopharynx	4	0	0	0	0	0	0	0	0	0	0	0.3	0.9	0	0	3	0	7.9	0.1	0.3	
C12-C13	Hypopharynx	4	0	0	0	0	0	0	0.2	0.2	0	0.2	0	0	1.3	0	0	0	0	0.1	0.1	
C14	Pharynx unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Oesophagus	11	1	0	0	0	0	0	0.4	0.4	0.3	0	0	0	2.7	0	0	4.7	7.9	0.3	0.5	
C16	Stomach	24	1	0.3	0	0	0	0	0	1	0.8	1.1	0	0.9	1.3	3.7	0	4.7	7.9	0.6	0.7	
C17	Small intestine	5	0	0	0	0	0	0	0	0.2	0	0	0.7	0.9	0	0	3	0	0	0.1	0.2	
C18	Colon	75	5	0	0	0	0	1.3	0.4	1	0.5	1.2	2.6	4.4	9.4	29.9	6.1	37.6	31.7	1.8	4.1	
C19-C20	Rectum	24	1	0	0	0	0	0	0.2	0.2	0.2	0	2	2.6	4	5.6	9.1	9.4	0	0.6	1.2	
C21	Anus	2	0	0	0	0	0	0	0	0	0	0	0.3	0	1.3	0	0	0	0	0	0.1	
C22	Liver	13	1	0	0	0	0	0	0	0	0.2	0.2	0.3	0	5.4	0	3	9.4	15.9	0.3	0.9	
C23-C24	Gallbladder etc.	10	0	0	0	0	0	0	0	0	0	0	0.3	0	4	1.9	9.1	9.4	0	0.2	0.7	
C25	Pancreas	23	2	0	0	0	0	0	0	0.2	0.2	0	1.3	2.6	8	1.9	6.1	4.7	15.9	0.5	1.3	
C30-C31	Nose, sinuses etc.	5	0	0	0	0	0	0	0	0	0.5	0	0	0	0	1.9	3	0	0	0.1	0.2	
C32	Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1.3	0	0	0	0	0	0.1	
C33-C34	Trachea,Bronchus,Lung	30	2	0	0	0	0	0	0.2	0.4	0.3	0.4	1	2.6	1.3	7.5	15.2	14.1	15.9	0.7	1.8	
C37-C38	Other Thoracic organs	4	0	0	0	0	0	0	0	0	0.2	0	0.3	0	1.3	1.9	0	0	0	0.1	0.2	
C40-C41	Bone	30	0	1	0.5	1.3	0.4	0.4	0.2	0	0.3	0.7	0.3	1.7	0	5.6	9.1	4.7	15.9	0.7	1.4	
C43	Melanoma of Skin	5	0	0	0	0	0	0	0	0	0.2	0	0	0.9	0	1.9	0	0	15.9	0.1	0.4	
C44	Other Skin	24	0	0	0	0.3	0	0	0.2	0.2	0.2	0.7	0.7	3.5	1.3	3.7	6.1	9.4	23.8	0.6	1.4	
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C46	Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0
C47;C49	Connective,Soft tissue	28	1	0	0.8	0.3	0	0.8	0.4	1	0.3	0.4	0.3	2.6	1.3	5.6	0	4.7	7.9	0.7	1	
C50	Breast	646	8	0	0	0	0	0.4	3.7	11.4	15.5	19.6	30.6	70.9	83	93.5	109.2	94	119	15.1	23.4	
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C52	Vagina	1	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0
C53	Cervix Uteri	36	0	0	0	0	0	0	0	1.2	0.3	0.5	3.9	3.5	2.7	3.7	0	18.8	7.9	0.8	1.3	
C54	Corpus Uteri	64	0	0	0	0	0	0	0.2	1	0.2	1.4	1.6	4.4	16.1	15	36.4	9.4	39.7	1.5	3.8	
C55	Uterus unspec.	20	0	0	0	0	0	0	0	0	0.3	0.9	1	1.7	1.3	5.6	3	4.7	15.9	0.5	1	
C56	Ovary	45	0	0	0.3	0.3	0.4	0	0.4	0.8	1.8	0.7	2.3	8.7	1.3	0	6.1	4.7	0	1.1	1.2	
C57	Other Female Genital	6	0	0	0	0	0	0	0.2	0	0	0.2	0	1.7	0	0	0	4.7	7.9	0.1	0.4	
C58	Placenta	1	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0
C64	Kidney	16	0	0	0.3	0	0	0.4	0	0	0.2	0	1.3	1.7	4	3.7	0	4.7	7.9	0.4	0.8	
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C67	Bladder	13	0	0	0	0	0	0	0	0.2	0	0	0	1.7	6.7	3.7	0	14.1	0	0.3	0.8	
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	2	0	0	0	0	0	0	0	0	0.2	0	0	0	1.3	0	0	0	0	0	0	0.1
C70-C72	Brain, Nervous system	39	0	0.7	1.3	1.3	0	1.7	0.6	0.4	0.3	0.4	1.3	2.6	2.7	3.7	9.1	0	7.9	0.9	1.5	
C73	Thyroid	116	3	0	0	0	1.2	2.1	2.3	5.2	3.5	3.2	2.6	10.5	4	7.5	0	0	15.9	2.7	2.7	
C74	Adrenal gland	2	0	0	0.3	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0
C75	Other Endocrine	1	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin disease	34	2	0.3	0.5	0.3	1.2	1.3	1	1.2	0.5	0.2	0.7	1.7	2.7	0	0	0	7.9	0.8	1	
C82-C85;C96	Non-Hodgkin lymphoma	40	1	0	0.3	0	0.8	0.8	0	1.2	0.5	0.9	1	7	6.7	0	3	14.1	0	0.9	1.4	
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	14	0	0	0	0	0	0	0	0	0.2	0	0.7	2.6	4	0	9.1	4.7	7.9	0.3	0.9	
C91	Lymphoid Leukaemia	33	0	2.3	4.4	1.3	0.8	0.4	0	0	0.2	0.2	0	0	0	0	0	0	0	0.8	1	
C92-C94	Myeloid Leukaemia	27	0	0.3	0.5	0.3	0.8	0.4	0.4	0	0.2	0.5	0.7	3.5	2.7	1.9	6.1	4.7	15.9	0.6	1.3	
C95	Leukaemia unspec.	17	0	1.6	0.8	0	0.4	0	0	0	0.2	0	0.3	0.9	1.3	1.9	6.1	4.7	0	0.4	0.8	
Other	Other & unspecified	53	0	0.3	0	0.3	0	0	0.2	0.4	0.8	1.6	1.6	8.7	14.7	7.5	0	9.4	15.9	1.2	2.2	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	1572	28	7	10	6	6	10	12	29	29	36	61	161	203	223	264	305	444	36.8	63	
Not C44	All sites but C44	1548	28	7	10	5	6	10	12	29	29	35	60	157	202	219	258	296	421	36.3	61.7	

ACKNOWLEDGEMENT

We would like to express our deepest gratitude to the following champions for their invaluable contribution and support for the 2020 Report.

Based on Alphabetical order

1- Asser Central Hospital:

Mr. Ibrahim saeed algamdi
Eng. Mohammed Meateqal Qahtani
Eng. Marwan Mohammed Abu Ali

2- Abu Arish general hospital:

Mr. Mohammed Hussain Ayashi

3- Armed Forces Hospital Southern region:

Mr. Ali Saeed Almarri
Mr. Amer Mohammed alshehri

4- Almana general hospital Eastern region:

Mr. Khaled Abdulhady Ali
Ms. Amnah Jafer Aljishi
Ms. Maryem Ahmed Albuayjan

5- Alhada Armed Forces Hospital:

Ms. Marifah Abdullah Khawjah

6- Care National Hospital:

Mr. Manea Saleh Alyami

7- Dammam Medical Complex:

Dr. Mohammed Dhafir AlAhmari
Mr. Ahmed Abdullah Masood
Ms. Alaa Fathi Al-Habib
Ms. Khatoon Hussain Al-Bahrani

8- Dr. Sulaiman Al Habib Group:

Dr. Mehwish Ateeq
Ms. Alaa Abdulaziz BinAyeed
Ms. Loreta Umlas Zapanta
Ms. Nora Casuga Ramos
Ms. Cristine Faye Rojo Tacan
Ms. Haya Abdulrahman Al Dawood
Ms. Ahood Nasser Abdullah Alsaig
Mr. Ghalib AlDarbi
Ms. Essra Salah Aldeen Alkhalifa

9- International medical center hospital:

Ms. Rema alhebshi
Ms. Elham alsulami

10- Jazan Regional Health Laboratory:

Mr. Mohammed Abdu Muqarbish

11- Johns Hopkins Aramco Healthcare:

Ms. Maram AlAbbad
Ms. Munirah AlQahtani
Ms. Amal AlShehri
Ms. Anne Walters

12- King Abdulaziz Medical City for National guard in Riyadh:

Mr. Abd Rahman Albiaby
Mr. Sultan Bin Taleb

13- King Abdulaziz Medical City for National guard in Jeddah:

Dr. Mubarak Almansour

14- King Abdulaziz university hospital:

Dr. shadi Alkhayatt

15- King Abdullah medical city:

Dr. Hussein elsayed
Ms. Asmaa Saeed Almadani

16- King Fahad Medical City:

Dr. Muhammad Nasir Khan
Mr. Awadh Saleh Alamri
Ms. Noura Alanzi
Ms. Thekra Bin shouil
Mr. Abdullah Alanazi
Ms. Nouf Alquhtani
Ms. Amani aljaber

17- King Saud University hospital:

Mr. Shaikh Mohiuddin

18- King Fahad armed forces hospital:

Dr. eman alhazmi

Dr. sara altayyb

Dr. ehab taha

Dr. waleed alsyyad

Dr. semsem mushtaq

Dr. bahaa allethi

Mr. rayan althobaity

19- King Fahad Specialist Hospital, Tabuk:

Ms. Khadija Yahya Alkaabi

20- King Fahad Hospital, Hofuf:

Dr. Ibraheem Khalifa Al- Hanoot

Dr. Hisham Abdulrahman Al-Eissa

Mrs. Jawaher Ahmed Al-Hemaid

Mrs. Abrar Mohammed Al-Hamad

Mr. Maytham Taqi Al-Haddad

Mr. Mohammed Abdulwahab Al-Aithan

Mr. Ibrahim Mohammed Al-Habib

Mr. Omar Muhanna Al-Muhani

Mr. Habeeb Hussain Al-Jubran

Dr. Jawad Hussain Al-Khalaf

Mr. Habib Khalifa Binkhalaf

21- Prince Faisal bin Bandar Center, King Fahd Specialist Hospital, Buraidah:

Mr. Mohsen Abdellatif Gadelhak

22- King Khalid General Hospital, Hail:

Mr. Ammar mohammed Almithen

23- King Abdulaziz Specialist Hospital, Al-Jouf:

Mr. Ahmed abu el gasim Abdelrahman dafaalla

24- Kingdom Hospital:

Roselle Taruc Tagao

Lito Bergonzado

25- King Khaled Eye Specialist Hospital:

Ms. Reem Abdullah AlKhodair

26- King Khalid General Hospital, Hail:

Mr. Ahmed Awadh alanazi

27- King Fahd Central Hospital, Jazan:

Mr. Ahassan Mohd Hussin Ashwi

Mr. Dinesh Chengalil

28- King Fahad Specialist hospital in Dammam:

Dr. Mohammed Rahal

Ms. Aisha Alsowayigh

Ms. Arwa Alswailem

Ms. Fatima Almulhim

Ms. Norah AlDossari

Ms. Munirah Alqahtani

29- King Fahad Hospital of the University:

Prof. Dr. Ali M Al-Amri , MD

Mrs. Kholoud Mohammed Al-Ikhwan.

Dr. Abrar Ahmed Al-Farid.

Prof. Dr. Mohammed Saeed Al-Shahrani, MD

30- King Faisal Specialist Hospital & Research Centre in Riyadh:

Ms. Doha Fatani

Ms. Salma Aljared

Mr. Mohamed Alammari

Mr. Abdul Rasim Thurakkal

Ms. Rehab Alsawi

Mr. Faisal Alanazi

31- King Faisal Specialist Hospital & Research Centre in Jeddah:

Ms. Laila Banjar

Mr. Majed Naser

Ms. Rawan Hariri

Mr. Adel Alamari

32- King Saud Medical City (KSMC):

Mr. Nabeel Khalil Gohoum

33- Maternity and Children Hospital

Dammam:

Dr. Bassam Alhejili
Dr. Fatimah Al-yousef
Dr. Sukinah Al-Talaq
Ms. Dalia Ali Alouf
Ms. Fatimah Al-Khazal
Ms. Alaa Redah Alhargan
Ms. Amal Roudh Alshaalan
Ms. Maryam Ahmed Almeshkhas

34- Mouwasat Hospital:

Dr. Khalid Qassam GHallab
Dr. Hebatallah Madkour
Ms. Prajeesha Pakkarath
Ms. Marwa Almassari
Ms. Noura Alrammah
Ms. Reem A. Alshmmari
Ms. Reem alyami

35- Prince Mohammed Bin Nasser Hospital,

Jazan:

Mr. Essa Hassan Jeffery

36- Specialized Medical Center hospital in

Riyadh:

Dr. hasan masoud
Ms. Nazeek abdelaziz
Ms. Melyn Escobar

37- Prince Sultan Oncology Center, King

Salman Armed Forces Hospital, Tabuk:

Mr. Osama Mukhtar

38- Saudi German Hospital – Aseer:

Mr. Mohammed Qasim
Ms. Amjad Mesfer Alshehri

39- Samtah General hospital:

Mr. Ahmed Chalfan Hantool

40- Sabya General Hospital:

Mr. Abdulrhman eissa Meary

41- Security Forces Hospital Makkah:

Mr. Abdulaziz obied alwuthaynani
Ms. Hatoon Mohammed Badawood



ARABIC SUMMARY



السرطانات العشرة الأكثر شيوعاً بين السعوديين لكلا الجنسين:

احتل سرطان الثدي بين النساء المرتبة الأولى (٢٤٥٩ حالة) بنسبة ١٧,٨٪ تلاه سرطان القولون والمستقيم (١٧٣٩ حالة) بنسبة ١٢,٣٪ ثم سرطان الغدة الدرقية (١٠٤٤) بنسبة ٧,٤٪ ثم سرطان ابيضاض الدم (٨٣٥ حالة) بنسبة ٥,٩٪ ثم سرطان اللمفاوي اللاهودجكن (٧٥٦ حالة) بنسبة ٥,٤٪ يليه سرطان اللمفاوي هودجكن (٥٨١ حالة) بنسبة ٤,١٪ ثم سرطان الرحم (٤٩٤ حالة) بنسبة ٣,٥٪ يليه سرطان الجهاز العصبي (٤٨٨ حالة) بنسبة ٣,٥٪ ثم سرطان الرئة (٤٥٨ حالة) بنسبة ٣,٣٪ وأخيراً سرطان الكبد (٤٥٠ حالة) بنسبة ٣,٢٪.

السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين لكلا الجنسين:

احتل سرطان ابيضاض الدم المرتبة الأولى (٢٣٦ حالة) بنسبة ٣٠,٨٪ تلاه سرطان الجهاز العصبي (١٢٨ حالة) بنسبة ١٦,٧٪ ثم السرطان اللمفاوي هودجكن (١٢٥ حالة) بنسبة ١٦,٣٪ ثم السرطان العظام (٥٢ حالة) بنسبة ٦,٨٪ ثم سرطان اللمفاوي اللاهودجكن (٣٩ حالة) بنسبة ٥,١٪، ثم سرطان الكلى (٣٣ حالة) بنسبة ٤,٣٪، ثم سرطان الأنسجة الضامة والرخوة (٢٤ حالة) بنسبة ٣,١٪، يليه سرطان العين (٢٣ حالة) بنسبة ٣,٠٪، و سرطان الغدة الكظرية (٢٣ حالة) بنسبة ٣,٠٪ وأخيراً سرطان المبيض (١١ حالة) بنسبة ١,٤٪.

السرطانات العشرة الأكثر شيوعاً بين السعوديين لكلا الجنسين:

الإنثا	7841	%	الذكور	6209	%
الثدي	٢٤٥٩	٣١,٤	القولون والمستقيم	٩٦٦	١٥,٦
الغدة الدرقية	٨١٦	١٠,٤	ابيضاض الدم	٤٩٤	٨,٠
القولون والمستقيم	٧٦٣	٩,٧	اللمفاوي اللاهودجكن	٤٢٠	٦,٨
الرحم	٤٩٤	٦,٣	البروستاتا	٣٦٦	٥,٩
ابيضاض الدم	٣٤١	٤,٣	الرئة	٣٥٣	٥,٧
اللمفاوي اللاهودجكن	٣٣٦	٤,٣	اللمفاوي هودجكن	٣٤٧	٥,٦
المبيض	٢٣٤	٣,٠	الكبد	٢٩١	٤,٧
اللمفاوي هودجكن	٢٣٤	٣,٠	المثانة	٢٩١	٤,٧
الدماغ والجهاز العصبي	٢٠٥	٢,٦	الدماغ والجهاز العصبي	٢٨٣	٤,٦
الكبد	١٥٩	٢,٠	الكلى	٢٢٨	٣,٧

السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين لكلا الجنسين:

الإنثا	315	%	الذكور	451	%
ابيضاض الدم	٩٥	٣٠,٢	ابيضاض الدم	١٤١	٣١,٣
اللمفاوي هودجكن	٤٧	١٤,٩	الدماغ والجهاز العصبي	٨٤	١٨,٦
الدماغ والجهاز العصبي	٤٤	١٤,٠	اللمفاوي هودجكن	٧٨	١٧,٣
العظام	١٩	٦,٠	العظام	٣٣	٧,٣
الكلى	١٧	٥,٤	اللمفاوي اللاهودجكن	٢٩	٦,٤
العين	١٢	٣,٨	الكلى	١٦	٣,٥
الأنسجة الضامة والرخوة	١١	٣,٥	الأنسجة الضامة والرخوة	١٣	٢,٩
المبيض	١١	٣,٥	الغدة الكظرية	١٢	٢,٧
الغدة الكظرية	١١	٣,٥	العين	١١	٢,٤
اللمفاوي اللاهودجكن	١٠	٣,٢	الكبد	٦	١,٣

إحصائيات السرطان في المملكة العربية السعودية لعام ٢٠٢٠

السجل السعودي للأورام

أنشئ السجل السعودي للأورام في عام ١٤١٢ هـ (١٩٩٢م) بمستشفى الملك فيصل التخصصي ومركز الأبحاث تحت إشراف وزارة الصحة وبمشاركة من القطاعات الصحية الحكومية. يضم السجل خمسة فروع في مناطق المملكة بالإضافة إلى وجود مكاتب في عدد من القطاعات الصحية. بدأ السجل نشاطه في جمع المعلومات من شهر يناير في عام ١٩٩٤ م، حيث يتم جمع وترميز البيانات وتدخل حسب النظام المعتمد من منظمة الصحة العالمية وتحلل البيانات بشكل دوري. يقوم السجل بتزويد الجهات المختصة والباحثين بمعلومات إحصائية وفق نموذج خاص على صفحة السجل في الموقع الرسمي للمجلس الصحي السعودي:

[HTTPS://SHC.GOV.SA/ARABIC/NCC/ACTIVITIES/PAGES/ANNUALREPORTS.ASPX](https://shc.gov.sa/arabic/ncc/activities/pages/annualreports.aspx)

إحصائيات السرطان لعام ٢٠٢٠

بلغ إجمالي عدد حالات السرطان المكتشفة في عام ٢٠٢٠ والمسجلة من مختلف المرافق الصحية الحكومية والخاصة بالمملكة العربية السعودية ١٧٢٩١ حالة، من بين هذه الحالات ١٤٠٥٠ سعوديين بنسبة ٨١,٣٪ وغير سعوديين ٣٢٤١ بنسبة ١٨,٧٪. وكان عدد حالات السرطان لدى السعوديين الذكور ٦٢٠٩ حالة بنسبة إجمالية قدرها ٤٤,٢٪ بينما بلغ عدد الحالات لدى الإناث السعوديات ٧٨٤١ حالة بنسبة إجمالية قدرها ٥٥,٨٪.

غير سعوديين			سعوديين			المجموع الكلي
المجموع	أثى	ذكر	المجموع	أثى	ذكر	١٧٢٩١
٣٢٤١	١٥٧٢	١٦٦٩	١٤٠٥٠	٧٨٤١	٦٢٠٩	

بلغ المعدل المعياري للإصابة بالسرطان بين الرجال ٧٤,٧ حالة لكل ١٠٠٠٠٠ نسمة، وبين النساء ٩٢,١ حالة لكل ١٠٠٠٠٠ نسمة. سجلت المنطقة الشرقية أعلى معدل لحدوث حالات السرطان بين الذكور بمعدل عمري معياري ١١٤,٦ حالة لكل ١٠٠٠٠٠ نسمة تلتها منطقة الرياض بمعدل ١٠٦,٢ حالة لكل ١٠٠٠٠٠ نسمة، ثم منطقة نجران بمعدل ٨٠,٢ حالة لكل ١٠٠٠٠٠ نسمة ثم منطقة تبوك بمعدل ٧٣,٢ حالة لكل ١٠٠٠٠٠ نسمة، ومنطقة الجوف بمعدل ٦٥,٨ لكل ١٠٠٠٠٠ نسمة. كما بلغت المعدلات العمرية المعيارية للإصابة بالسرطان لدى النساء بالمنطقة الرياض ١٥٣,٥ حالة لكل ١٠٠٠٠٠ نسمة تليها المنطقة الشرقية بمعدل ١٢٥,٥ حالة لكل ١٠٠٠٠٠ نسمة، ثم منطقة تبوك بمعدل ٨٤,٤ حالة لكل ١٠٠٠٠٠ نسمة ثم منطقة الجوف بمعدل ٨٢,٦ حالة لكل ١٠٠٠٠٠ نسمة ومنطقة القصيم بمعدل ٧٨,٩ حالة لكل ١٠٠٠٠٠ نسمة.

الملخص العربي
تقرير معدل الإصابة بمرض السرطان
المملكة العربية السعودية
٢٠٢٠

الحمد لله والصلاة والسلام على رسول الله وعلى آله وصحبه ومن والاه، أما بعد:



يضطلع المركز الوطني للسرطان بالمجلس الصحي السعودي بأدوار مهمة تتمثل في جمع وتبويب وتحليل بيانات حالات السرطان في المملكة العربية السعودية للعام ٢٠٢٠م والتأكد من سلامتها، وذلك بمشاركة من جميع القطاعات الصحية الحكومية والأهلية في المملكة.

ويواصل المركز الوطني للسرطان على أداء السجل لمهامه بفعالية وتقديم الدعم الإداري والفني، والاستفادة من الإحصائيات المتراكمة في وضع أولويات مكافحة السرطان وعلاجه ووضع البرامج

الوطنية المناسبة في هذا الشأن، وتطوير وتحسين مستويات الرعاية الصحية المقدمة لمرضى السرطان.

ويعد السجل السعودي للأورام الذي أنشئ في عام ١٤١٢هـ / ١٩٩٢م، من أوائل السجلات الوطنية في المملكة، حيث كان يخضع لإشراف وزارة الصحة بمستشفى الملك فيصل التخصصي ومركز الأبحاث الذي استضاف السجل إلى حين انتقاله لمقره الجديد في المجلس الصحي السعودي في عام ١٤٣٥هـ / ٢٠١٤م.

ويلاحظ في تقرير هذا العام تأثير جائحة فيروس كورونا ١٩ على أعداد المصابين المسجلين بالسرطان في عام ٢٠٢٠ في المملكة العربية السعودية نتيجة لفترات الإغلاق والتي أدت إلى نقص في أعداد الحالات المسجلة بنسبة ١٢٪ مقارنة بالأعداد المسجلة في عام ٢٠١٩ وهذه النسبة تتماشى مع ما سجل في بقية دول العالم بنسب تتراوح ما بين ١٠٪ إلى ٢٠٪. ويتوقع زيادة الأعداد في العام ٢٠٢١ بسبب تأخر التشخيص أثناء فترات الإغلاق.

ختاماً؛ أسعد بتقديم جزيل الشكر إلى الفريق الفني القائم على إعداد وتنفيذ هذا التقرير من الزملاء والزميلات بالمركز الوطني للسرطان ومسجلي السرطان في كافة القطاعات الصحية على جهودهم المبذولة في إنجاز هذا العمل الكبير، والشكر موصول إلى جميع أعضاء اللجنة العلمية للسرطان وللمراجعين هذا التقرير على ما قدموه من جهود ملموسة في السجل الوطني للأورام، بما يخدم القطاع الصحي لخدمة المواطن والمقيم.

أ.د. مشبب بن علي العسيري

مدير عام

المركز الوطني للسرطان

بسم الله الرحمن الرحيم



يحتوي التقرير السنوي لأعمال السجل السعودي للأورام لعام ٢٠٢٠م، الذي يقدمه المجلس الصحي السعودي ممثلاً في المركز الوطني للسرطان؛ على إنجازات السجل وأنشطته وبرامجه التي قام بها مؤخراً حيث تدعم التقارير التي يصدرها السجل الجهود المبذولة في مجال مكافحة السرطان، وتزود القائمين على المشاريع العلاجية والتثقيفية بالبيانات التفصيلية الدقيقة للسرطان؛ والتي تشخص الوضع الحقيقي لحالات السرطان في المملكة، وتحدد أكثر أنواعه شيوعاً حسب النوع والعمر والموقع الجغرافي.

كما تتيح تقارير السجل لأصحاب القرار، التخطيط لاستحداث مراكز لعلاج مرض السرطان والتصدي له، وكذلك برامج التثقيف الصحي للوقاية منه، تماشياً مع الاستراتيجيات الوطنية والأهداف الصحية التي أعدها المجلس الصحي السعودي، المتضمنة التنسيق والتكامل بين الجهات المعنية بالصحة؛ لتحسين وتعزيز الرعاية الصحية؛ وفق رؤية المملكة ٢٠٣٠، لتحقيق تطلعات القيادة الحكيمة والمواطنين والمقيمين.

ختاماً؛ إن ما يشهده القطاع الصحي في وطننا الغالي من تطور ملموس ومشاهد؛ جاء أولاً بفضل من الله تعالى ثم بدعم حكومتنا الرشيدة بقيادة خادم الحرمين الشريفين وسمو ولي عهده الأمين -حفظهما الله، ومتابعة معالي رئيس المجلس الصحي السعودي وأعضاء المجلس، ولا يفوتني في هذا المقام أن أقدم الشكر الجزيل إلى الزملاء والزميلات في المجلس الصحي السعودي ممثلاً بالمركز الوطني للسرطان على عملهم الدؤوب وجهدهم المستمر الذي قاموا به لإعداد هذا التقرير وتحقيق رسالة السجل وأهدافه لتسجيل حالات السرطان كافة في المملكة، والشكر موصول إلى كافة منسوبي القطاع الصحي والهيئات والمؤسسات والجمعيات الخيرية الذين أولوا مرضى السرطان عناية كبيرة وقاموا بإعداد البرامج العلاجية والتوعوية للوقاية من هذا المرض في المملكة.

د. نهار بن مزكي العازمي

الأمين العام للمجلس الصحي السعودي

تقرير
معدل الإصابة
بمرض السرطان
2020

تقرير معدل الاصابة بمرض السرطان 2020

تحت رقم إيداع 1445/1117 وتاريخ 1445/01/27 هـ، ورقم ردمد 1658-9807



المجلس الطبي السعودي
Saudi Health Council



المجلس الطبي السعودي
Saudi Health Council

المملكة العربية السعودية
المجلس الصحي السعودي
المركز الوطني للسرطان
السجل السعودي للأورام

تقرير
معدل الإصابة
بمرض السرطان
2020